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ABSTRACT 
 
In vitro studies suggest that fatty acid bind protein 1 (Fabp1) and sterol carrier protein 
2/sterol carrier protein x (Scp2/Scpx) gene products facilitate the uptake, metabolism and 
detoxification of dietary phytol in mammals. In fact, individually ablating FABP1 or SCP2/SCPx 
each impairs hepatic branched-chain fatty acid uptake and/or metabolism. Studies also suggest 
that singly ablating Fabp1 or Scp2/Scpx genes may exacerbate the impact of a high fat diet on 
whole body phenotype and non-alcoholic fatty liver disease (NAFLD). However, concomitant 
upregulation of FABP1 in SCP2/SCPx null mice complicates interpretation of each protein’s 
physiological role in studies where only one of these proteins has been ablated. Therefore, the 
impact of ablating both Fabp1 and Scp2/Scpx genes was explored in phytol and high fat diet fed 
mice. 
In the phytol study, triple gene ablation (TKO) increased hepatic total lipid accumulation, 
primarily phospholipid, by mechanisms involved in increasing hepatic levels of proteins in the 
phospholipid synthesis pathway while reducing expression of proteins in targeting fatty acids 
towards the triacylglycerol synthesis pathway. Concomitantly, TKO also reduced expression of 
proteins in targeting fatty acids towards the triacylglycerol synthesis pathway. In the high fat 
study, wild type (WT) male mice exhibited higher hepatic lipid accumulation than WT females 
and TKO increased hepatic lipid accumulation in both. The greater hepatic lipid accumulation in 
WT males was associated with high hepatic expression of enzymes in glyceride synthesis, higher 
hepatic bile acids and upregulation of transporters involved in hepatic reuptake of serum bile 
acids. The TKO-induced increases in hepatic glycerides were attributed to sex dependent 
upregulation of hepatic lipogenic enzymes.  
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Overall, since individually ablating the Scp2/Scpx gene elicits the upregulation of the 
FABP1 protein, these findings with TKO mice help to resolve the contributions of Scp2/Scpx 
gene ablation on dietary phytol and high fat induced whole body and hepatic lipid phenotype 
independent of concomitant upregulation of FABP1.  
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NOMENCLATURE 
 
3αHSD 3alpha-hydroxysteroid reductase: An intracellular bile acid binding protein 
that plays a significant role in bile acid biosynthesis, steroid hormone 
metabolism, and xenobiotic metabolism, displays a pattern of liver 
specific expression, and functions to inactivate circulating steroid 
hormones. 
ABCA1 ATP-binding cassette sub-family A member 1: A membrane-associated 
protein involved in nascent HDL formation. With cholesterol as its 
substrate, it functions as a cholesterol efflux pump in the cellular lipid 
removal pathway. 
ABCG1, 4, 5 or 8 ATP-binding cassette sub-family G member 1, 4, 5 or 8: Involved in 
hepatic HDL secretion: critically involved in the regulation of lipid-
trafficking mechanisms in macrophages, hepatocytes, and intestinal 
mucosa cells. ABCG1 participates in cholesterol and phospholipid efflux. 
ABCG4 plays an important role in cellular cholesterol homeostasis and 
functions as either a homodimer or as a heterodimer with another ABC 
subfamily protein such as ABCG1. The ABCG5 and ABCG8 transporters 
are also targets in the control and influence of total body sterol 
homeostasis. 
ACAT2 Acetyl-CoA acetyltransferase (Soat2 gene): An enzyme in cholesterol 
esterification. Cholesterol is essential for efficient intestinal cholesterol 
 viii 
 
absorption, and may control the amount of hepatic free (unesterified) 
cholesterol available for secretion into bile or into HDL.  
ACC1 Acetyl-CoA carboxylase (Acaca gene): An enzyme that catalyzes the 
irreversible carboxylation of acetyl-CoA to produce malonyl-CoA for the 
biosynthesis of fatty acids. When the enzyme is active, the product, 
malonyl-CoA, is produced, which is a building block for new fatty acids 
and can inhibit the transfer of the fatty acyl group from acyl CoA to 
carnitine with carnitine acyltransferase, which inhibits the beta-oxidation 
of fatty acids in the mitochondria. 
ACBP Acyl CoA Binding Protein: A small (10 Kd) protein that binds medium- 
and long-chain acyl-CoA esters with very high affinity and may function 
as an intracellular carrier of acyl-CoA esters.  
ACOX1  Peroxisomal acyl-CoA oxidase-1 (Acox1 gene): The first enzyme of the 
fatty acid beta-oxidation pathway, which catalyzes the desaturation of 
acyl-CoAs to 2-trans-enoyl-CoAs. 
AFABP Adipocyte Fatty Acid Binding Protein (FABP4): A member of the 
intracellular fatty acid binding protein (FABP) family, which is known for 
the ability to bind fatty acids and related compounds. Its gene is critical in 
the regulation of the biological function of differentiated adipocytes and 
may be involved in mediating obesity-induced alterations in adipocyte 
gene expression. 
AGPAT  1-acylglycerol-3-phosphate-O-acyltransferase (Agpat2 gene): An 
adipokine which acylates lysophosphatidic acid at the sn-2 position to 
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produce phosphatidic acid in the phospholipid and triglyceride synthesis 
pathway. 
ALT  Alanine Aminotransferase: An enzyme found mostly in the cells of the 
liver and kidney that converts alanine into pyruvate, an important 
intermediate in cellular energy production. When the liver is damaged, 
ALT is released into the blood, which makes ALT a useful test for 
detection of liver damage. 
APOA1  Apolipoprotein A1: A component of high-density lipoprotein (HDL), 
which is a molecule that transports cholesterol and phospholipids through 
the bloodstream from the tissues to liver. 
APOB Apolipoprotein B: A component of very low-density lipoproteins 
(VLDLs), intermediate-density lipoproteins (IDLs), and low-density 
lipoproteins (LDLs), all of which transport fats, including cholesterol, in 
the bloodstream. Apolipoprotein B-100 allows these particles to attach to 
specific receptors on the surface of cells, particularly in the liver. The 
receptors transport low-density lipoproteins into the cell, where they are 
broken down to release cholesterol. The cholesterol is then used by the 
cell, stored, or removed from the body. 
AST Aspartate Transaminase: Catalyzes the reversible transfer of an α-amino 
group between aspartate and glutamate so is therefore an important 
enzyme in amino acid metabolism. AST is found in the liver, heart, 
skeletal muscle, kidneys, brain, and red blood cells. Serum AST levels, 
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along with serum ALT levels, are commonly measured clinically as 
biomarkers for liver health. 
BA β-actin: A western blotting normalization protein/housekeeper. 
BFABP Brain fatty acid binding protein (FABP7). A member to the family of 
intracellular lipid-binding proteins involved in fatty acid uptake and 
intracellular transport in the brain. FABP7 is also important in brain 
development. 
β-HOB β-hydroxybutyrate: A ketone body and a physiological measure of fatty 
acid oxidation.  
BSEP  Bile salt export pump (Abcb11 gene): A unidirectional, ATP-dependent 
efflux transporter that plays an important role in the elimination of bile 
salts from liver cells into bile canaliculi for export into the gastrointestinal 
tract.  
C Free cholesterol: A measure of the circulating cholesterol that has not been 
esterified and accounts for about 30% of the total cholesterol in plasma.  
Cholesterol esterification occurs before or after it is released into the 
circulation, and esterification with any physiologically relevant fatty acid 
enhances the lipid-carrying capacity of lipoproteins and prevents 
intracellular toxicity by free cholesterol. 
CE Cholesteryl ester. The preferred form of cholesterol for transport in plasma 
and as a biologically inert storage or de-toxification form to buffer an 
excess. Cholesterol esters do not contribute to membrane structures but are 
packed into intracellular lipid droplets in the cytoplasm. 
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COX4 Cytochrome c oxidase subunit IV: A western blotting normalization 
protein/housekeeper. 
CPT1a or 2 Carnitine palmitoyltransferase 1a and 2 (Cpt1a or 2 gene): CPT1a, located 
in the outer mitochondrial membrane, is the rate-limiting enzyme for 
mitochondrial beta oxidation. CPT2, located in the inner mitochondrial 
membrane, is also involved in mitochondrial beta oxidation. Long-chain 
fatty acids cannot enter mitochondria unless they are attached to a 
substance known as carnitine. CPT1A connects carnitine to long-chain 
fatty acids so they can cross the inner membrane of mitochondria. Once 
these fatty acids are inside mitochondria, CPT2 removes the carnitine and 
adds coenzyme A. Long-chain fatty acids must be joined to coenzyme A 
before they can be metabolized to produce energy. 
CRABP1 Cellular retinoic acid binding protein 1: A specific binding protein for 
retinoic acid, a metabolite of vitamin A (retinol) that mediates the 
functions of vitamin A required for growth and development. It is thought 
to play an important role in retinoic acid-mediated differentiation and 
proliferation processes and may contribute to vitamin A-directed 
differentiation in epithelial tissue.   
CYP7A1 Cytochrome P7A1 (Cyp7a1 gene). The rate-limiting enzyme in bile acid 
biosynthesis from cholesterol. High cholesterol diets induce Cyp7A1 gene 
expression in mice, and the induction of this gene is mediated via 
oxysterol metabolites of cholesterol-activating LXR, which directly 
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regulates transcription of Cyp7A1. Therefore, LXR upregulates Cyp7a1 
when cholesterol is high.  
DEXA Dual energy X-ray absorptiometry: Measures body composition in terms 
of fat and fat-free mass. DEXA generates X-rays at two different energies 
and makes use of the differential attenuation of the X-ray beam at these 
two energies to calculate the bone mineral content and soft tissue 
composition in the scanned region.  
DGAT Diacylglycerol acyltransferase (Dgat2 gene): Catalyzes the formation of 
triacylglycerol from diacylglycerol and acyl-CoA. The reaction catalyzed 
by DGAT is the terminal and only committed step in triglyceride 
synthesis, and is essential for adipose tissue formation. 
FABP1/LFABP Liver fatty acid binding protein: A fatty acid binding protein that is 
primarily expressed in the liver, where it is involved in binding, transport 
and metabolism of long-chain fatty acids, endocannabinoids, 
phytocannabinoids and other hydrophobic molecules. Altered expression 
of this protein has been linked to metabolic disorders such as obesity. 
FASN Fatty acid synthase (Fasn gene): A multi-enzyme protein that catalyzes 
fatty acid synthesis. Its main function is to catalyze the synthesis of 
palmitate from acetyl-CoA and malonyl-CoA, in the presence of NADPH. 
Its expression is reduced by PPARα.  
FATP2, 4, and 5 Fatty acid transport protein 2, 4 and 5: These proteins facilitate the 
transport of long-chain fatty acids across plasma and intracellular 
membranes.  
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FTM Fat tissue mass: A loose connective tissue composed primarily of 
adipocytes.   
FXR Farnesoid x receptor: Reduces bile acid synthesis. When activated by its 
bile acid ligands, FXR translocates to the cell nucleus, forms a 
heterodimer with RXR and induces the down-regulation of Cyp7A1, the 
rate-limiting enzyme in bile acid synthesis from cholesterol.  
GAPDH Glyceraldehyde 3-phosphate dehydrogenase: A western blotting 
normalization protein/housekeeper. 
GOT Glutamic oxaloacetic transaminase: See AST.  
GPAT Glycerol-3-phosphate acyltransferase (Gpam gene): A rate-limiting 
enzyme of triacylglycerol and phospholipid biosynthesis by catalyzing the 
synthesis of lysophosphatidic acid from glycerol-3-phosphate and long-
chain acyl-CoA.  
GST Glutathione s-transferases: Metabolic isozymes with the ability to catalyze 
conjugation of the reduced form of glutathione (GSH) to xenobiotic 
substrates for detoxification and excretion in the bile or urine. GST are 
also involved in bile acid cytosolic transport, and are inhibited by bile 
acids. 
HDL-C  High density lipoprotein cholesterol: Known as the "good" cholesterol 
because it helps remove other forms of cholesterol from the bloodstream 
rather than their accumulation within vessels. Higher levels of HDL 
cholesterol are associated with a lower risk of heart disease. 
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HMGCR 3-hydroxy-3-methylglutaryl-CoA reductase: The rate-limiting enzyme of 
the mevalonate pathway, the metabolic pathway that produces cholesterol. 
This enzyme is directly inhibited by statins, drugs to treat cardiovascular 
disease by reducing serum cholesterol. 
HMGCS1 Cytosolic 3-hydroxy-3-methylglutaryl-CoA synthase: An enzyme which 
catalyzes the reaction in which Acetyl-CoA condenses with acetoacetyl-
CoA to form HMG-CoA. It is the second reaction in the mevalonate-
dependent cholesterol biosynthesis pathway.  
HSL/CEH Hormone sensitive lipase/cholesteryl ester hydrolase: Mediates the 
degradation of triglycerides and formation of free fatty acids (FFA). To be 
utilized as an energy source, FFAs must be transported from the peripheral 
tissues into the mitochondria of hepatocytes. Once inside the 
mitochondria, FFAs undergo beta oxidation, which converts them into 
acetyl coenzyme A (acetyl-CoA).  
 I-FABP Intestinal fatty acid binding protein (FABP2): Participates in the uptake, 
intracellular metabolism and/or transport of long-chain fatty acids.  
 I-FABP is present in small intestine epithelial cells and liver.  
LDL-R Low density lipoprotein receptor: Mediates the endocytosis of cholesterol-
rich LDL and thus maintains the plasma level of LDL. This occurs in all 
nucleated cells, but mainly in the liver, which removes ~70% of LDL from 
the circulation. Synthesis of receptors in the cell is regulated by the level 
of free intracellular cholesterol; if in excess, transcription of the receptor 
gene is inhibited. 
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Lipin 2  Phosphatidate phosphatase (Lpin2 gene): An intracellular protein in the 
endoplasmic reticulum (ER) that functions as a phosphatidic acid 
phosphohydrolase enzyme (PAP-1) to catalyze the penultimate step in 
triglyceride synthesis.  
LTM Lean tissue mass: A component of body composition calculated by 
subtracting body fat weight from total body weight 
 LXR Liver X receptor: A ligand-activated transcription factor expressed in the 
liver and functions as physiological receptors for oxidized cholesterol 
metabolites, oxysterols. LXR plays an important role in the regulation of 
bile acid biosynthesis by regulating the expression of CYP7A1, the rate-
limiting enzyme in bile acid biosynthesis. Because production of bile acids 
from cholesterol is the metabolic pathway for degradation of cholesterol, 
LXRs serve as “cholesterol sensors” to provide levels of CYP7A1 
expression that maintain appropriate concentrations of cholesterol.  
MDR2 Multidrug resistance protein 2 (ABCB4): Localized in the canalicular 
membranes of hepatocytes, MDR2 is necessary for the secretion of 
phospholipids into bile.  Fibrates induce Mdr2 gene expression and biliary 
phospholipid secretion in the mouse.  
MRP2 Multidrug resistance associated protein: Hepatic proteins in cytosolic 
phosphatidylcholine transport and canalicular secretion into bile. 
MTP Microsomal triglyceride transfer protein. A protein involved in secretion 
of cholesterol as VLDL. 
NEFA Non-esterified fatty acid: Free fatty acid, usually the result of hydrolysis. 
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Non-HDL-C Non-HDL cholesterol: Total cholesterol minus HDL cholesterol. Total 
cholesterol is the sum of LDL, HDL, and very-low-density lipoproteins 
(VLDL). VLDL carry triglycerides to tissues and eventually become LDL. 
Like LDL, it also causes cholesterol to build up on the inside of arteries, 
creating artery-clogging plaque. The higher the LDL and VLDL levels, the 
higher the risk of heart disease. 
NTCP Sodium taurocholate cotransporting polypeptide: A sodium-dependent 
uptake transporter expressed on the basolateral (blood-side) membrane of 
hepatocytes. It is primarily responsible for the uptake of bile acids from 
the sinusoids. NTCP is one of the key transporters in the enterohepatic 
circulation of bile acids.  
 OATP1 or 2 Organic anion-transporting polypeptide 1 or 2 (Slco1a1 or Slc22a7 genes, 
respectively):  A membrane transport protein that mediates the transport of 
mainly organic anions across the cell membrane including bile acids as 
well as bilirubin and numerous hormones such as thyroid and steroid 
hormones across the basolateral membrane in hepatocytes, for excretion in 
bile.  
PCTP Phosphatidylcholine transfer protein: A specific intracellular phospholipid 
binding protein that can transfer phosphatidylcholine between different 
membranes in the cytosol. 
PL Phospholipid: A class of lipids that are a major component of all cell 
membranes. They can form lipid bilayers because of their amphiphilic 
characteristic. The structure of the phospholipid molecule generally 
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consists of two hydrophobic fatty acid "tails" and a hydrophilic "head" 
consisting of a phosphate group. The two components are joined together 
by a glycerol molecule.  
PPARα  Peroxisome proliferator activated receptor alpha: A transcription factor 
and major regulator of lipid metabolism in the liver. Its activation 
promotes uptake, utilization, and catabolism of fatty acids by upregulating 
genes involved in fatty acid transport, fatty acid binding and activation, 
and mitochondrial and peroxisomal fatty acid β-oxidation. It is primarily 
activated through ligand binding. Synthetic ligands include fibrates, which 
are used to treat cardiovascular disease caused by hyperlipidemia.  
qRT-PCR  Quantitative real-time polymerase chain reaction: qRT-PCR quantitatively 
detects gene expression through the creation of complementary DNA 
(cDNA) transcripts from RNA using fluorescent dyes.  
RXRα Retinoid x receptor α: An important regulator of cell growth and 
differentiation both in fetal and in adult tissues. It is a ligand-inducible 
transcription factor that belongs to the superfamily of nuclear hormone 
receptors and is specifically activated by retinoic acid. RXRα forms 
heterodimers with PPAR-α, which bind peroxisome proliferator receptor 
elements (PPREs) in and around genes regulated by PPAR-alpha. 
SCP2 Sterol carrier protein 2: An intracellular lipid transfer protein that mediates 
transfer of all common phospholipids, cholesterol and gangliosides 
between membranes and may play a role in regulating steroidogenesis. 
The Scp2 gene encodes both the SCP2 and SCPx proteins. The transcript 
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initiated from the proximal promoter encodes the longer SCPx protein, 
and the transcript initiated from the distal promoter encodes the shorter 
SCP2 protein, with the 2 proteins sharing a common C-terminus. 
SCPx Sterol carrier protein x: A peroxisome-associated thiolase that is involved 
in the oxidation of branched chain fatty acids. It is encoded by the Scp2 
gene (see SCP2).  
SEM Standard error of the mean: A measure of the statistical accuracy of an 
estimate, equal to the standard deviation of the theoretical distribution of a 
large population of such estimates. The standard deviation is divided by 
the square root of the number of measurements. 
SHP Short heterodimer partner: FXR does not directly bind to the CYP7A1 
promoter, but induces expression of small heterodimer partner (SHP), 
which then inhibits transcription of the CYP7A1 gene. In this way, a 
negative feedback pathway is established in which synthesis of bile acids 
is inhibited when cellular levels of bile acid are already high. 
SR-B1 Scavenger receptor class B member 1: A receptor for HDL that facilitates 
uptake of cholesteryl esters from HDL in the liver. This process drives the 
movement of cholesterol from peripheral tissues towards the liver (reverse 
cholesterol transport), where cholesterol can either be secreted via the bile 
or be used to synthesize steroid hormones. Reverse cholesterol transport is 
a protective mechanism against the development of atherosclerosis, which 
is the principal cause of heart disease and stroke.  
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SREBP1 and 2  Sterol regulatory element-binding protein 1 and 2: SREBP-1 is active in 
driving transcription of genes involved in fatty acid synthesis, whereas 
SREBP-2 is more active in stimulating transcription of genes involved in 
cholesterol biosynthesis. For example, SREBP 2 downregulates Cyp7a1 
when cholesterol is low, preventing cholesterol metabolism to bile acids.   
TC Total cholesterol: The sum of free cholesterol and cholesterol ester. 
TG Triglyceride/triacylglycerol: The simplest lipids formed by fatty acids. TG 
is made up of three fatty acid esters linked to a single glycerol. Most 
triacylglycerols contain two or three different fatty acids. TGs are 
nonpolar, hydrophobic, and insoluble in water. 
TKO Triple knock-out: The TKO in these studies were fatty acid binding 
protein1/sterol carrier protein-2/sterol carrier protein-x null mice on a 
C57BL/6NCr background (Fabp1/Scp2/Scpx null or gene-ablated mice) 
WT Wild-type C57BL/6 mice 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW1 
 
Metabolic syndrome is a constellation of clinical findings associated with a significantly 
increased risk for cardiovascular disease and type 2 diabetes. The clinical findings associated 
with metabolic syndrome include abdominal obesity, high serum glucose, high serum 
triglycerides, low serum high-density lipoprotein cholesterol and hypertension (1). Diseases 
associated with metabolic syndrome are amongst the leading causes of preventable death in the 
United States (2). In addition, metabolic syndrome also has an association with other health 
problems including non-alcoholic fatty liver disease (NAFLD) which is the most common of all 
liver disorders, occurring in 10–58% of the US population (3-7).  
While the biochemical basis for neither metabolic disease nor NAFLD is completely 
understood, three potential liver lipid binding proteins have been identified as potential 
contributing candidates: First is the hepatic fatty acid binding protein (FABP1). Genomic studies 
suggest that a very prevalent SNP in human FABP1 resulting in a T94A amino acid substitution 
is highly associated with NAFLD and reduced ability of hypolipidemic drugs to lower serum 
triglycerides to target levels (8, 9). FABP1 is the single most prevalent liver cytosolic protein 
that binds, transports, and targets bound lipidic ligands such as long chain fatty acids and their 
CoA thioester (10, 11), endocannabinoids (12), bile acids (13), cholesterol (14), and lipidic 
                                                 
11. Reprinted from Milligan S, Martin GG, Landrock D, et al. Ablating both Fabp1 and Scp2/scpx (TKO) induces 
hepatic phospholipid and cholesterol accumulation in high fat-fed mice. Biochim Biophys Acta. 2018;1863(3):323-
338. doi: S1388-1981(18)30004-0 [pii]. 2018 
2.Reprinted from Milligan S, Martin GG, Landrock D, et al. Impact of dietary phytol on lipid metabolism in 
SCP2/SCPX/L-FABP null mice. Biochim Biophys Acta. 2017;1862(3):291-304. doi: S1388-1981(16)30328-6 [pii]. 
2017 
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xenobiotics (8, 15, 16) to intracellular organelles for storage, oxidation, receptor regulation, or 
gene regulation. FABP1 also has high affinity for branched-chain lipids such as phytol-derived 
phytanic and pristanic acids (17, 18). In vitro studies with cultured cells show that FABP1 
enhances the uptake and peroxisomal oxidation of branched-chain fatty acids (19-21). FABP1 
has even been detected within peroxisomes, suggesting that it may not only chaperone bound 
branched-chain fatty acyl-CoA to peroxisomes but also to oxidative enzymes within peroxisomes 
(22). 
Another candidate is sterol carrier protein-2 (SCP2) which also chaperones lipidic ligands 
associated with the development of metabolic disease and NAFLD. SCP2 binds, transports, and 
targets bound lipidic ligands such as long chain fatty acids and their CoA thioesters (23-25), 
endocannabinoids(26, 27), bile acids (28), cholesterol (29, 30), and phospholipids (24, 31, 32) to 
intracellular organelles for storage, oxidation, excretion, or receptor regulation. In addition, 
SCP2 and SCPx, both encoded by the same SCP2/SCPx gene through alternate transcription 
sites, are important contributors to branched-chain fatty acid metabolism (3). Like FABP1, SCP2 
has no enzymatic activity, but binds branched-chain lipids such as phytol-derived phytanic and 
pristanic acids (23). SCP2 was also shown to enhance branched-chain fatty acid cellular uptake 
and metabolism (33). Hepatic SCP-2 concentration is about 6–8 fold less than that of FABP1 
(29, 34), with half in cytosol and the remainder primarily concentrated in peroxisomes (28, 35, 
36). Within the peroxisomal matrix, SCP2 directly interacts with fatty acid oxidative enzymes, 
suggesting a role in presenting bound branched-chain fatty acyl CoAs to these enzymes to 
facilitate their oxidation (37). In contrast to SCP2 and FABP1, SCPx is localized exclusively in 
peroxisomes (28, 38, 39). SCPx functions as a ketothiolase enzyme with substrate specificity for 
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both straight-chain and branched-chain fatty acids (38, 40-43). SCPx is the only known 
peroxisomal ketothiolase enzyme for β-oxidation of branched-chain fatty acids (42). 
In our nutritional studies, we sought to investigate the impact of both a high phytol and a 
high fat diet on Fabp1/Scp2/Scpx knock-out mice. Phytol, a saturated sixteen-carbon chain-
length fatty alcohol with four methyl branches, is released by ruminant bacterial cleavage of 
chlorophyll's side-chain for further conversion to branched-chain fatty acids (44). While 
branched-chain fatty acids are often present at significant levels in meat and dairy products, 
serum levels are normally low due to rapid hepatic uptake and metabolism (45-47). However, in 
peroxisomal disorders of branched-chain fatty acid oxidation, serum and hepatic branched-chain 
fatty acid levels reach toxic levels (45, 46). Branched-chain fatty acids such as phytanic acid 
have functional similarity to fibrates, hypolipidemic drugs used to treat cardiovascular disease, 
diabetes and metabolic syndrome (48, 49). High fat diets, one of the major contributors to the 
development of metabolic syndrome, have also been shown to induce NAFLD (3, 4, 6, 7, 50, 
51). Studying the effects of both a high phytol and high fat diet in mice lacking FABP1, SCP2 
and SCPx will shed significant new insights into the roles of these proteins as they relate to 
whole body phenotype and hepatic lipid metabolism, two strong areas of intertest in the study of 
metabolic syndrome associated diseases.  
It is also important to study the effects of a high phytol and high fat diet in TKO mice in 
the context of sexual dimorphism as studies have already shown significant differences in males 
in females concerning fatty acid metabolism.  For example, FABP1, SCP2 and SCPx are all 
intrinsically lower in female than male mice. In fact, FABP1 levels are not only sex specific, 
they also increase during pregnancy and lactation (34). Fabp1 gene ablation decreased hepatic 
triglyceride accumulation in fasted male, but not in female, mice fed standard commercial or 
 4 
 
defined control diets, while increasing hepatic cholesteryl ester accumulation in fasted female, 
but not in male mice fed standard commercial or defined control diet (34). Along with control 
diets, sexual dimorphism has been demonstrated in the metabolism of a phytol diet as well. For 
example, male and female mice with lowered SCPx have different responses to phytol in lipid 
parameters and hepatotoxicity. Females, but not males demonstrated the following: i) increased 
liver mass and decreased fat tissue mass; ii) histopathological lesions in the liver; and iii) 
significant changes in hepatic lipid distributions (47). Lastly, while Fabp1 silencing ameliorates 
hepatic steatosis, inflammation, and oxidative stress in high fat diet fed male mice with NAFLD 
(52), the impact of sex differences in the context of high fat diet has not been addressed and 
although ablating the Scp2/Scpx gene decreases hepatic lipid accumulation in control rodent 
chow fed male mice (53), the impact of sex differences especially in the context of HFD are 
unclear. 
Next, it is important to illustrate the significance of using a pair-feeding scheme versus an 
ad libitum feeding scheme for our nutritional studies. Mice strongly prefer a high fat diet and 
will consume more of it in ad libitum conditions. This phenomenon can significantly skew many 
aspects of the study, including whole body composition and lipid metabolic pathways. Therefore, 
there is a need for controlled, pair-fed dietary studies to study the impact of TKO independent of 
increased total intake of food. 
The present biochemical and morphological investigations sought to determine the effects 
of genotype, sex and diet on these mice. Previous work has been published that outlined the 
effects of a high phytol diet on TKO male mice. Therefore, this work focuses on female mice fed 
a high phytol diet and male and female mice fed a high fat diet. Since individually ablating the 
Scp2/Scpx gene elicits the upregulation of the FABP1 protein, this study with TKO mice helps to 
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resolve the contributions of Scp2/Scpx gene ablation on dietary phytol and high fat induced 
whole body and hepatic lipid phenotype independent of concomitant upregulation of FABP1. 
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CHAPTER II 
MATERIALS AND METHODS2 
Materials 
Triacylglycerol (L-type Triglyceride M, TG), free cholesterol (free cholesterol, C), total 
cholesterol (cholesterol E, TC), phospholipid (phospholipid, PL) and non-esterified fatty acid 
(HR Series NEFA-HR, NEFA) diagnostic kits from Wako Chemicals (Richmond, VA) were 
used to determine levels of the respective lipids. β-Hydroxybutyrate (β-hydroxybutyrate 
LiquiColor, β-HOB) and high-density lipoprotein cholesterol (Direct HDL-Cholesterol, HDL-C) 
diagnostic kits from Stanbio Laboratory (Boerne, TX) were used to determine levels of β-HOB 
and HDL-C. Apolipoprotein B (APOB) and apolipoprotein A-I (APOA1) levels were measured 
using diagnostic kits from Diazyme Labs (Poway, CA). A Bradford protein micro-assay (Cat # 
500-0001, bovine gamma globulin) from Bio-Rad (Hercules, CA) was used to determine protein 
levels. All reagents and solvents used were of the highest grade available. 
Generation of Fabp1 Null Mice 
To generate Fabp1 null mice, primers 5′-gacctcatccagaaagggaag and 5′-
cttttccccagtcatggtctc were designed to amplify from mouse DNA a 156-bp exon 2 fragment. The 
amplicon was used as a probe in Southern blotting and to screen a P1–129/Ola genomic library 
(Genome Systems). Extensive restriction mapping and southern blotting of mouse genomic and 
P1 DNA demonstrated the identity of the P1 clones with the respective genomic regions and the 
                                                 
21. Reprinted from Milligan S, Martin GG, Landrock D, et al. Ablating both Fabp1 and Scp2/scpx (TKO) induces 
hepatic phospholipid and cholesterol accumulation in high fat-fed mice. Biochim Biophys Acta. 2018;1863(3):323-
338. doi: S1388-1981(18)30004-0 [pii]. 2018 
2.Reprinted from Milligan S, Martin GG, Landrock D, et al. Impact of dietary phytol on lipid metabolism in 
SCP2/SCPX/L-FABP null mice. Biochim Biophys Acta. 2017;1862(3):291-304. doi: S1388-1981(16)30328-6 [pii]. 
2017 
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absence of pseudogenes. Mouse Fabp1 cDNA was used to confirm the identity of the P1 clones 
by southern hybridization and PCR for exons 1 and 4. An 8-kb EcoRV fragment containing the 
5′ gene flank plus exons 1 and 2 was subcloned from a P1 clone and used to isolate a 3.9-kb end-
filled EcoRV/EcoRI fragment (“long arm”) that in turn was ligated into vector pTVO (cut with 
XhoI and end-filled), a plasmid carrying the neomycin resistance marker, to create an 
intermediate long arm construct. A 10-kb SacI fragment overlapping the above EcoRV fragment 
and containing the whole gene as well as its 3′ flank was subcloned from P1 and used to isolate a 
1.3-kb BamHI/SalI fragment from the 3′ flank (“short arm”). The short arm was then ligated into 
the long arm construct (opened with BamHI and SalI), resulting in the targeting vector. The 
SalI/EcoRI fragment just 3′ of the short arm was partially sequenced to design primers. The 
targeting construct was opened with NotI and electroporated into HM1 cells. After selection with 
G418, colonies were screened by PCR for homologous recombination, using primers 5′-
ccttctatcgccttcttgacgag and 5′-agcctccagggattggaatg and an annealing temperature of 63 °C. 
These primers correspond to the neo resistance marker and the 3′ genomic flank outside of the 
construct, respectively. A fragment of the expected size of 1.4-kb was amplified in 5 out of 200 
clones, and 2 clones were expanded and injected into C57Bl/6 blastocysts to create chimeric 
mice by standard procedures. Heterozygous mice were obtained by breeding the chimeras with 
C57Bl/6 wild type mice, and experimental wild type and Fabp1 null mice were created by 
interbreeding of the first-generation heterozygous mice. Some of these mice were used to verify 
the gene deletion as follows. Liver DNA was purified by standard procedures and used as a 
template for long PCR to amplify an 8-kb fragment from wild type and a 2.5-kb fragment from 
Fabp1 null DNA. Cycling conditions were 96 °C, 30 s; 32× (94 °C, 30 s; 63 °C, 30 s; 68 °C, 8 
min). One primer (5′-ttcaagcctccagggattggaatg) corresponded to a sequence located immediately 
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3′ of the short arm homology region (i.e. outside of the recombination construct), the other 
primer (5′-cctggactgagacttgcctggattg) to a sequence located at the 3′-end of the long homology 
arm. The long PCR products were further verified by nested PCR for a 157-bp fragment of exon 
2, using primers 5′-ccgaggacctcatccagaaag and 5′-tccccagtcatggtctccag at an annealing 
temperature of 60 °C. With the same exon 2 primers, absence of exon 2 was also verified directly 
on genomic DNA. In addition, absence of exons 3 and 4 in knockout DNA was also directly 
confirmed by PCR with genomic DNA. After verification of the targeted gene deletion, another 
PCR assay was designed for routine single-tube genotyping of tail biopsies. Primers 5′-
caagggggtgtcagaaatcgtgc and 5′-ccagtcatggtctccagttcgca amplify 123 bp from exon 2 of the wild 
type allele, and 5′-aagagcttggcggcgaatgg and 5′-tggccatttgtggctgtgctc amplify 227 bp from the 
neomycin resistance marker into the 3′ flank of both alleles. An annealing temperature of 68 °C 
was used. Total liver RNA was isolated with the TRIzol reagent from Invitrogen (Carlsbad, CA), 
and reverse transcription was performed with random hexamer primers and Moloney murine 
leukemia virus reverse transcriptase (Invitrogen) according to a standard procedure. Aliquots of 
the RT reaction were used for PCR, using Fabp1 primers (5′-ctcattgccaccatgaacttctc and 5′-
agccttgtctaaattctcttgctgact, amplifying 404 bp) and hypoxanthine phosphoribosyl transferase 
(HPRT) primers (5′-gcttgctggtgaaaaggacctct and 5′-ggaaatcgagagcttcagactcgtc, amplifying 584 
bp) at an annealing temperature of 62 °C.  
Chimeric mice were bred with C57BL/6 mice, and the resulting heterozygous offspring 
were interbred and backcrossed to produce the L-FABP null (–/–) and wild type (+/+) littermate 
control mice for 4-7 generations. 
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Generation of Scp2/Scpx Ablated Mice 
Scp2/Scpx ablated mice were generated by targeted disruption of the Scp2 gene through 
homologous recombination. The targeting construct was designed to replace exon 16 with the 
neomycin cassette of the pUnivec-HPRT vector (a generous gift from Dr. Ramiro Ramírez-Solis, 
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX). 
Briefly, a genomic 129/sv Lambda FIX® library (Stratagene, La Jolla, CA) was screened with a 
150 bp DNA fragment containing exon 16 of the Scp2 gene. Positive clones were confirmed by 
extensive restriction mapping and sequence analysis. Two consecutive genomic DNA fragments, 
a 2.0 kb PstI clone (containing intronic sequences upstream of exon 16) and a 4.5 kb PstI clone 
(containing intronic sequences immediately upstream of exon 16, exon 16 itself, and intronic 
sequences downstream of exon 16) formed the backbone of the targeting construct. The 3′ 
homology arm was generated by ligating a blunt-ended 2.6 kb XbaI fragment from the 4.5 kb 
PstI clone into Litmus 39 vector (New England Biolabs, Ipswich, MA) predigested with EcoRV. 
This plasmid was digested with SacI/PstI and ligated with an 875 bp fragment from the 4.5 kb 
PstI clone digested with SacI/PstI. The resulting vector was digested with BamHI/HindIII to give 
a 2,824 bp fragment that was ligated into the pGEM-3Zf vector (Promega, Madison, WI) 
predigested with BamHI/HindIII. Digestion with EcoRI/HindIII released the 3′ homology region 
(with an incorporated KpnI site later used for Southern blot screening). The 3′ homology 
fragment was blunt-ended with T4 DNA polymerase and ligated into the pUnivec-HPRT vector 
(predigested with NotI and blunted with T4 DNA ligase) to yield an intermediate targeting 
construct named pUni+3′ vector. The 5′ homology region was prepared by digesting the 4.5 kb 
PstI clone with AccI/PstI to isolate a 2,562 bp fragment that was then ligated to an AccI/PstI 
fragment isolated from the 2.0 kb PstI clone. Digestion with BamHI/AccI released the 5′ 
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homology fragment. The targeting construct was completed by blunt-end ligation of the 5′ arm 
into the intermediate construct pUni+3′ vector (predigested with NheI and then blunted with T4 
DNA polymerase). Once complete, the targeting construct was opened with ClaI and 
electroporated into a 129/Ola-derived embryonic stem cell line E14 maintained on feeder layers. 
After selection with G418 (200 μg/ml) and gancyclovir (2 μM), DNA was isolated from 
surviving clones, digested with KpnI, and screened by Southern blot analysis according to 
standard protocols. Using a 200 bp 5′ probe external to the targeting construct, targeted clones 
were identified by the presence of a 6 kb band indicating that exon 16 was replaced with the 
neomycin cassette of pUnivec-HPRT vector. Three positive clones were expanded and injected 
into C57BL/6NCr blastocysts to create chimeric mice by standard procedures. Three male 
chimeras were identified by coat color and bred to C57BL/6NCr females to determine germline 
transmission of the targeted allele. Tail DNA from mixed coat-colored (agouti) F1 offspring was 
screened by PCR to verify the genotype of each animal. Initial characterization of the Scp2 gene 
ablation by Western analysis was performed on F2 Scp2−/− homozygous mice generated by 
interbreeding heterozygous F1 animals. The heterozygous F1 animals were backcrossed to a N6 
C57BL/6NCr background before interbreeding to produce the Scp2/Scpx null mice. 
Generation of TKO Mice  
Scp2/Scpx null mice were crossed with Fabp1 null mice to produce Fabp1−/+/Scp2/Scpx−/+ 
mice, which were then intercrossed to produce Fabp1−/−/Scp2/Scpx−/− triple-null (TKO) mice. 
Fabp1/Scp2/Scpx null (TKO) mice were backcrossed> 10 generations to the C57BL/6NCr 
background. The term TKO refers to loss of all three proteins even though they are encoded by 
only two genes (i.e. Fabp1 and Scp2/Scpx). Mice were housed in controlled conditions (T= 25 
°C, H = 60–70% added humidity) and 12:12 h light/dark cycle. Mouse protocols were approved 
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by the Texas A&M Institutional Animal Care and Use Committee in compliance with the Guide 
for the Care and Use of Laboratory Animals. Mice were monitored daily for injury or disease, 
sentinel monitored quarterly, and were shown free of all known rodent pathogens. 
Dietary Phytol Study  
           One week before the study, all mice were moved from a standard pelleted rodent chow to 
a modified AIN-76A phytol-free, phytoestrogen-free pelleted control diet (5% calories from fat, 
diet no. D11243, Research Diets, New Brunswick, NJ). The control diet was used to minimize 
potential complications due to phytoestrogens (which exert estrogenic effects on the central 
nervous system, induce estrus, and stimulate growth of the genital tract of female animals) (1) or 
phytol metabolites (e.g. phytanic acid), known to be the most potent naturally-occurring fatty 
acid ligand inducers of PPARα (2-4). After the one week on control chow, test mice were 
transferred to a modified AIN-76A pelleted rodent diet supplemented with 0.5% phytol (5% 
calories from fat, diet no. D01020601, Research Diets, New Brunswick, NJ), which is 
approximately ten times the total amount of free phytol and phytanic acid on average available in 
commercial laboratory rodent diets (5). Humans consume 50-100 mg of dietary phytol and 
phytanic acid per day (6). The mice fed the 0.5% phytol diet ingested ∼250 mg of phytol per 
day. Although dairy products such as butter, margarine, and cheeses can contain up to 500 mg 
phytanic acid/100 g wet weight (6), substantial amounts would need to be ingested to reach 
levels equivalent to those consumed in the 0.5% phytol feeding study (700 g/70 kg/day for 
human consumption). Phytol toxicity is not normally a problem with healthy individuals. 
However, it becomes an issue with peroxisomal disorders, such as Refsum's disease, which result 
in an inability to metabolize phytol (6).  
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           Two feeding groups contained 8 animals each which were fed ad libitum: (a) WT mice 
fed the 0.5% phytol diet, and (b) TKO mice fed the 0.5% phytol diet. The study was stopped 
after seven days because TKO mice exhibited a low tolerance for the 0.5% phytol diet, which 
manifested as a 20% percent loss in body weight. Body weight and food intake were measured 
every other day. 
Dietary High Fat Study 
Two groups of 16 each WT male, WT female, TKO male, and TKO female mice aged 7 
weeks were individually housed in Tecniplast Sealsafe IVC cages with external water bottles and 
wire lid holders for food pellets. Mice were acclimated for 1 week on a defined, 10 kcal% fat 
control chow (#D12450B, Research Diets, New Brunswick, NJ) known to be free of phytol and 
phytoestrogen for reasons described above. In each group of 16 individually- housed mice, 8 
mice were continued an additional 12 weeks on this same defined diet while the other 8 mice 
were pair-fed based upon food weight an isocaloric high fat diet (HFD, # D12451, Research 
Diets, New Brunswick, NJ). The high fat diet was formulated by modifying the defined control 
diet by increasing fat from 10 kcal% to 45 kcal% while decreasing carbohydrate from 70 kcal% 
to 35 kcal% while keeping protein constant as described (7). 
Whole Body Phenotype by Dual-Energy X-ray Absorptiometry (DEXA) 
To determine fat tissue mass (FTM) and lean tissue mass (LTM), mice were anesthetized 
at the beginning (day 0) and end (day 7) for the phytol study and end day 84 for the high fat 
study) using a ketamine/xylazine mixture (0.01 mL/g body weight; 10 mg ketamine/mL and 1 
mg xylazine/mL in 0.9% saline solution). Dual-energy X-ray absorptiometry (DEXA) images of 
each mouse were obtained using a Lunar PIXImus densitometer (Lunar Corp., Madison, WI) 
after calibration using a phantom mouse with known bone mineral density and fat tissue mass. 
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Whole body fat tissue mass (FTM) and bone-free lean tissue mass (LTM) were obtained by 
exposing the entire mouse, minus the head region, to sequential beams of high- and low-energy 
X-rays and taking X-ray images on a luminescent panel. Soft tissue mass was differentiated from 
bone mass by measuring the ratios of attenuation at different energies followed by separating soft 
tissue mass into FTM and LTM. 
Animal Euthanasia 
At the end of the study after overnight fast, blood was collected from the anesthetized 
mice via cardiac puncture followed by cervical dislocation as the secondary form of euthanasia 
according to the AVMA Guidelines for the Euthanasia of Animals. Blood was coagulated 
overnight at 4 °C, followed by centrifugation at 14,000 rpm for 20 min at 4 °C to process to 
serum and stored at−80 °C for subsequent lipid and protein analysis, and final DEXA images 
were taken. 
Tissue Collection 
Likewise, livers were collected, flash frozen in liquid nitrogen, and stored at −80 °C for 
subsequent histopathology and analysis of lipids, western blotting, and/or qRT-PCR as described 
in the following sections. 
Liver Histopathology 
At the time of liver collection, liver slices were taken near the portal hepatis, fixed for 24 
h in 10% neutral buffered formalin, put into individual cassettes with 70% alcohol, processed 
and embedded in paraffin, sectioned (4–6 μm), and stained with hematoxylin and eosin for 
histological evaluation.  
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Liver Homogenization and Protein Analysis 
Liver samples (~0.1 g) were minced extensively followed by the addition of 0.5 mL PBS 
(pH 7.4) and homogenization with a motor-driven pestle (Tekmar Co, Cincinnati, OH) at 2000 
rpm. A Bradford protein micro-assay (Bio-rad, Hercules, CA) was used to determine protein 
levels in the liver homogenates according to the manufacturer's instructions. Protein levels were 
determined on aliquots of homogenates in Costar 96-well assay plates (Corning, Corning, NY) 
and read using a BioTek Synergy 2 micro-plate reader (BioTek Instruments, Winooski, VT). 
Liver and Serum Lipid Analysis 
Liver homogenate lipid classes (TG, free C, total C, PL, and NEFA) were measured using 
Wako diagnostic kits in accordance with the manufacturer's instructions. Liver cholesteryl ester 
concentration (CE) was determined by subtracting free (non-esterified) cholesterol concentration 
from the total concentration. Serum lipids (free C, total C), HDL-cholesterol (HDL-C)], APOA1 
and APOB levels were determined using commercially available diagnostic kits in accordance 
with the manufacturer's instructions. The assays were modified to support the use of 96-well 
plates and micro-plate reader as described above. Serum cholesteryl ester (CE) concentrations 
were calculated by subtraction of serum free C from serum total C. Serum non-HDL-C was 
calculated by subtracting serum HDL-C from serum total C. 
Western Blotting 
The following antibodies were used in Western blotting to determine protein levels in 
liver homogenates: Rabbit and goat polyclonal antibody to mouse acyl- 
CoA-binding protein (ACBP) (SC-23474), APOA1 (SC-23606), ATP-binding cassette sub-
family G members 1, 4, 5 and 8 (ABCG1, 4, 5 and 8) (SC-11150, SC-33825, SC-25796, SC-
30010),  brain fatty acid binding protein (B-FABP) (SC-30088), bile salt export pump (BSEP) 
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(SC-17294), carnitine palmitoyltransferase 1a (Cpt1a) (SC-31128), carnitine 
palmitoyltransferase 2 (Cpt2) (SC-20671), cellular retinoic acid binding protein 1 (CRABP I) 
(SC-10062), fatty acid transport protein 4 (FATP4) (SC-5834), farnesoid x receptor (FXR) (SC-
13063), glyceraldehyde 3-phosphate dehydrogenase (GADPH) (SC-13063), intestinal fatty acid 
binding protein (I-FABP) (SC-16063), multidrug resistance protein (MDR2) (SC-8313), LDL-
Receptor (LDL-R) (SC-11826), liver x receptor (LXR) (SC-1201), microsomal triglyceride 
transfer protein (MTP) (SC-33116), retinoid x receptor α (RXRα) (SC-553), sterol regulatory 
element- binding protein 1 (SREBP1) (SC-367), sterol regulatory element binding protein 2 
(SREBP2) (SC-8151), short heterodimer partner and small heterodimer partner (SHP) (SC-
15283), 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) (SC-27578), cytoplasmic 3-
hydroxy-3-methylglutaryl-CoA synthase (HMGCS1) (SC-33829), hormone sensitive lipase 
(HSL) (SC-25843), multidrug resistance associated protein 2 (MRP2) (SC-5770) and 
phosphatidylcholine transfer protein (PCTP) (SC-23672) were obtained from Santa Cruz 
Biotechnology (Dallas, TX). Rabbit and mouse polyclonal antibody to mouse acetyl-CoA 
acetyltransferase (ACAT2) (ab66259), APOB (ab31992), cytochrome c oxidase subunit IV 
(COX4) (ab16056), fatty acid transport protein 2 (FATP2) (ab83763) and fatty acid transport 
protein 5 (FATP5) (ab89008) were purchased from Abcam (Cambridge, MA). Sheep polyclonal 
antibody to bovine catalase (W90080C) was purchased from BioDesign (Dublin, OH). Rabbit 
polyclonal antibody to mouse glutamic oxaloacetic transaminase (GOT) (12248), FABP1 
(11294), SCP2 (12249), and SCPx (11306) were prepared as described (6, 8). Goat polyclonal 
antibody to mouse glutathione s-transferase (GST) (27457701V) was obtained from GE Life 
Sciences (Pittsburgh, PA). Bacterial polyclonal antibody to mouse 3alpha-hydroxysteroid 
reductase (3αHSD) (H9117-01) was from US Biological (Peabody, MA). Rabbit polyclonal 
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antibody to mouse PPARα (PA1-822A) was obtained from Pierce Antibody (Rockford, IL) and 
to mouse scavenger receptor class B member 1 (SR-B1) (NB400-104), ATP-binding cassette 
transporter member 1 (ABCA1) (NB400-105) from Novus Biological (Littleton, CO). Alkaline 
phosphatase-conjugated goat polyclonal antibody to rabbit IgG (product # A3687) and rabbit 
polyclonal antibody to goat IgG (product # A4187) were from Sigma-Aldrich (St. Louis, MO). 
Alkaline phosphatase-conjugated rabbit polyclonal antibody to mouse IgG (product # ab6729) 
was from Abcam (Cambridge, MA). Antibodies to housekeeper proteins were obtained as 
follows: Mouse monoclonal antibody to mouse GAPDH (MAB374) from Millipore (Billerica, 
MA); rabbit polyclonal antibody to mouse cytochrome c oxidase subunit IV (COX4) (ab16056) 
from Abcam (Cambridge, MA) and mouse polyclonal antibody to mouse β-Actin (BA) (SC-
47778) from Santa Cruz Biotechnology (Dallas, TX). Since the proteins of interest were 
differentiated by size from COX4, BA or GAPDH on the tricene gels, the membrane blots were 
cut into two, and each was probed with antisera against the protein of choice and against COX4, 
BA or GADPH housekeeper proteins to ensure uniform protein loading. Alkaline-phosphatase 
conjugated goat anti-rabbit or mouse IgG were used to visualize protein bands. Blot images were 
then obtained using an Epson Perfection V700 Photo scanner (Long Beach, CA) and image 
proteins (mean 8-bit grayscale density) quantitated by densitometric analysis using NIH Image 
(available by anonymous FTP). Levels of each protein were then normalized to the mean level of 
the respective housekeeper protein (COX4, BA or GAPDH). Proteins with no source of pure 
protein were expressed as relative fold differences between samples. Western blots where pure 
protein was available (SCPx, SCP2, FABP1, and ACBP in the phytol study) linear standard 
curves were generated for quantitative analysis. Band intensities on the Western blots were 
analyzed as described above and then plotted against the protein amount to generate a standard 
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curve within the linear range of each protein. Changes in protein expression between liver 
homogenate samples were quantitated by comparing the sample with the standard curve on each 
blot.  
Real-time Quantitative RT-PCR 
The following probes were obtained from Applied Biosystems (Foster City, CA) for 
quantitating gene specific mRNA levels in mouse liver homogenates as follows: glycerol-3-
phosphate acyltransferase (GPAT) (Gpam; Mm00833328_m1), 1-acylglycerol-3-phosphate-
Oacyltransferase (AGPAT) (Agpat2; Mm00458880_m1), Lipin 2 (Lpin2; Mm00522390_m1), 
diacylglycerol acyltransferase (DGAT) (Dgat2; Mm00499536_m1), acetyl-coA carboxylase 
(ACC1) (Acaca; Mm01304285_m1), acetyl-coA carboxylase (ACC1) (Acaca; 
Mm01304285_m1), fatty acid synthase (FASN) (Fasn; Mm00662319_m1), 3-hydroxy-3- 
methylglutaryl-CoA (HMGCR) (Hmgcr; Mm01282492_m1), 3-hydroxy- 
3-methylglutaryl-CoA synthase (HMGCS1) (Hmgcs1, Mm01282492_m1), sodium-taurocholate 
cotransporting polypeptide (NTCP) (Slc10; Mm01302718_m1), organic anion-transporting 
polypeptide 1 (OATP1) (Slco1a1; Mm01267414_m1), organic anion-transporting polypeptide 2 
(OATP2) (Slc22a7; Mm00460672_m1), carnitine palmitoyltransferase 1a (CPT1A) (Cpt1a; 
Mm00550438_m1), carnitine palmitoyltransferase 2 (CPT2) (Cpt2; Mm00487202_m1), acyl-
CoA oxidase-1 (ACOX1) (Acox1; Mm00443579_m1), acetyl-CoA acetyltransferase (ACAT2) 
(Soat2; Mm00448823_m1), bile salt export pump (BSEP) (Abcb11; Mm00445168_m1), sterol 
regulatory element-binding protein 2 (SREBP2) (Srebf2; Mm01306289_m1), cytochrome P7A1, 
CYP7A1 (Cyp7a1, Mm00484152_m1) and ATPbinding cassette sub-family G member 5 
(ABCG5) (Abcg5; Mm01226965_m1) and ATP-binding cassette sub-family G member 8 
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(ABCG8) (Abcg8; Mm00445977_m1). Briefly, total mRNA was isolated from livers and 
purified using an RNeasy minikit (Qiagen, Valencia, CA) as per the manufacturer's protocol. 
Concentrations and quality of mRNA were measured using the ND-1000 method (Nanodrop 
Technologies, Inc., Wilmington, DE) where a 260/280 ratio of 1.9–2.1 was accepted as mRNA 
of good quality. For qRT-PCR, expression patterns were assessed using TaqMan® One-Step 
PCR Master Mix reagent kit, gene-specific TaqMan PCR probes, and primers. An ABI PRISM 
7000 Sequence Detection System (Applied Biosystems, Foster City, CA) and thermal cycling 
conditions of 48 °C for 30 min, 95 °C for 10 min before the first cycle, 95 °C for 15 s and 60 °C 
for 1 min, repeated 40 times, were used for quantitating mRNA expression. Prior to 
amplification, total mRNA was first reverse transcribed in the first step of the thermal cycler 
protocol (48 °C for 10 min) using TaqMan one step chemistry. mRNA expression was 
normalized to 18S RNA (a housekeeping gene) and made relative to the control mouse group 
(male WT mice on high fat diet) set to one for final calculations. 
Statistics 
Data were expressed as averages ± standard error of the mean (SEM). For the phytol 
study, statistical analysis was performed using t-test (GraphPad Prism, San Diego, CA, San Jose, 
CA). Values with p < 0.05 were considered statistically significant. For the high fat study, 
statistical analysis was performed by one-way ANOVA followed by Newman-Keuls post hoc 
analysis (GraphPad Prism, San Diego, CA, San Jose, CA and Sigma Plot, Systat, San Jose, CA). 
Statistical differences of p < 0.05 were considered significant. 
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CHAPTER III 
PHYTOL STUDY RESULTS3 
Body Weight, Liver Weight, Liver Histopathology and Serum AST and ALT 
Dietary phytol significantly decreased weight gain in WT mice, an effect exacerbated by 
TKO (Chapter 3 Fig. 1A).  The phytol-induced weight loss was attributable to both reduced food 
consumption and reduced energy intake. Phytol decreased food consumption by 16+3% in WT 
and nearly twice as much by 29+2% in TKO mice (not shown). When body weight change was 
expressed on the basis of energy intake, i.e. body weight gain per kcals of food consumed, phytol 
decreased energy intake in WT mice, an effect markedly exacerbated nearly 3-fold in by TKO 
(Chapter 3 Fig. 1B). This suggested that TKO exacerbated the effect of dietary phytol on weight 
loss, not only by decreasing food intake but also by altering metabolism.   
 Dietary phytol was associated with mild hepatocellular necrosis in both WT and TKO (not 
shown). These observations were supported by measurement of serum values of ALT and AST, 
other indicators of hepatocyte damage. Although dietary phytol increase ALT and AST values 
similarly in both WT and TKO mice, all values were within the normal range of mouse serum 
ALT and AST values (less than 150 and 330 units/l, respectively) shown for blood chemistry and 
hematology in 8 inbred strains of mice, MPD: Eumorphia. Mouse Phenome Database web site, 
The Jackson Laboratory, Bar Harbor, Maine USA. http://phenome.jax.org [Cited 29 Oct, 2014]). 
Taken together, these measures indicated that the major changes in whole body and liver lipid 
                                                 
3 Reprinted from Milligan S, Martin GG, Landrock D, et al. Impact of dietary phytol on lipid metabolism in 
SCP2/SCPX/L-FABP null mice. Biochim Biophys Acta. 2017;1862(3):291-304. doi: S1388-1981(16)30328-6 [pii]. 
2017 
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phenotype elicited by TKO in phytol fed mice detailed in the following sections were not due to 
marked hepatotoxicity.   
Body Composition:  Fat Tissue Mass and Lean Tissue Mass 
PIXImus dual-energy x-ray absorptiometry (DEXA) scans were done to determine if any 
decline in weight gain, was due to selective loss of fat or protein. Representative PIXImus images 
of mice from the beginning (Chapter 3 Fig. 2A,B) and end (Chapter 3 Fig. 2C,D) of the dietary 
study suggested gross differences in body composition. Phytol-fed WT mice appeared visually 
smaller at the end of the study (Chapter 3 Fig. 2A,C). This difference appeared even more marked 
in phytol-fed TKO mice (Chapter 3 Fig. 2B,C). DEXA analysis of 8 mice to resolve FTM (Chapter 
3 Fig. 2E) and LTM (Chapter 3 Fig. 2F) showed that dietary phytol increased FTM while 
concomitantly decreasing LTM (Chapter 3 Fig. 2E,F).  In contrast, TKO decreased both FTM and 
LTM (Chapter 3 Fig. 2E,F). 
Hepatic Lipid and Glyceride Accumulation 
Phytol-fed TKO mice had markedly more total hepatic lipid than phytol-fed WT mice 
(Chapter 3 Fig. 3A). This change was attributed primarily to a nearly 3-fold increase in 
phospholipid (Chapter 3 Fig. 3C) while triacylglycerol actually decreased about 25% (Chapter 3 
Fig. 3D). Hepatic phospholipid accumulation was associated with a more than two-fold increase 
in expression of the key enzymes in synthesis of phosphatidic acid (precursor of both 
phospholipids and triacylglycerols), i.e. Gpam (Chapter 3 Fig. 3E) and Agpat (Chapter 3 Fig. 3F) 
and increased expression of Acc1, the rate limiting enzyme in de novo fatty acid synthesis (Chapter 
3 Fig. 4C).  Though Dgat is a key enzyme in the synthesis of triacylglycerol and was significantly 
higher in TKO mice than WT mice (Chapter 3 Fig. 3H), this increase was not reflected in hepatic 
triacylglycerol levels. On the contrary, triacylglycerol levels were significantly less in TKO mice. 
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This decrease is attributed to decreased expression of Fasn, a key enzyme in fatty acid synthesis 
(Chapter 3 Fig. 4C) and increased expression of Lipe a key enzyme in triacyglycerol hydrolysis.  
Taken together, these findings suggested that the TKO induced hepatic lipid accumulation 
by favoring fatty acyl targeting towards phospholipids at the expense of triacylglycerol in phytol-
fed TKO phytol-fed mice.    
Hepatic Fatty Acid Oxidation   
Hepatic glyceride accumulation in phytol-fed TKO mice may arise not only from increased 
de novo lipogenesis, but also from increased uptake and/or decreased oxidation of fatty acids.   
While loss of FABP1 and SCP-2, both facilitators of fatty acid uptake, was expected to 
increase serum non-esterified fatty acid (NEFA) level, on the contrary TKO did not significantly 
changes serum NEFA (Chapter 3 Fig. 5A). This lack of increase in serum NEFA was attributable 
in part to concomitant downregulation of two hepatic membrane fatty acid transporters, FATP5 
(Chapter 3 Fig. 5B) and GOT (Chapter 3 Fig. 5E). FATP2 and FATP4, however, remained 
unchanged (Chapter 3 Fig. 5C,D).   
TKO did not decrease hepatic (Chapter 3 Fig. 6B) or serum (Chapter 3 Fig. 6A) levels of 
-hydroxybutyrate (-OHB), a measure of hepatic fatty acid oxidation. This was reflected in no 
change in the levels of hepatic expression of key enzymes in mitochondrial (CPT1A, CPT2) or 
peroxisomal (p-thiolase) fatty acid -oxidation (Chapter 3 Fig. 6C,D,F). As expected, the other 
major enzymes in peroxisomal fatty acid -oxidation, i.e. SCPx (58kDa) and SCPx (43kDa), were 
not detectable in these TKO mice.  In addition, there was no significant change in the expression 
of nuclear receptors regulating transcription of fatty acid -oxidative enzymes (Chapter 3 Fig. 
6I,J).  
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Thus, the TKO-induced increase in hepatic glycerides was not associated with either 
increased expression of membrane transport proteins involved in fatty acid uptake or a decrease in 
fatty acid -oxidation. Instead, the TKO-induced increase in hepatic glyceride was associated with 
increased fatty acid synthesis, represented by an increase in key enzymes, particularly an increase 
in Acc1, the rate limiting enzyme in fatty acid synthesis (Chapter 3 Fig. 4C).  
Hepatic Cholesterol Accumulation 
The finding that TKO increased total neutral lipid, despite decreasing triacylglycerol, 
suggested upregulation of the other major neutral lipid species, cholesterol and/or cholesteryl ester 
perhaps as a result of the upregulated expression of target genes in cholesterol synthesis (Hmgcs1, 
Hmgcr) (Chapter 3 Fig. 4E,F). However, there was no effect on hepatic total cholesterol, free 
cholesterol or cholesteryl ester levels (Chapter 3 Fig. 7A-C) nor was there a change in the 
expression of the cholesteryl ester synthetic enzyme (acyl CoA cholesterol acyltransferase, ACAT 
2) (Chapter 3 Fig. 7D). In contrast, there was marked upregulation of hepatic expression of the 
Lipe gene, which codes for the degradative enzyme cholesteryl ester hydrolase (CEH) (Chapter 3 
Fig. 7E). Thus, upregulation of Lipe did not actively decrease hepatic cholesterol levels in phytol-
fed TKO.  
Serum Levels of Cholesterol and Lipoproteins in Serum Cholesterol Transport 
TKO significantly increased both serum cholesterol and cholesterol ester in phytol fed mice 
(Chapter 3 Fig. A,B). This increase is attributed to increased lipoprotein rich in apoB as well as 
increased non-HDL-C (Chapter 3 Fig. F, G) in the serum. These parameters, along with increased 
expression of Lipe, however, did not contribute to decreased hepatic accumulation of cholesterol. 
These findings suggest that TKO, in combination with phytol, has a “protective” effect against 
hepatic cholesterol accumulation.   
 31 
 
 
Hepatic Expression of Proteins Involved in Cholesterol Basolateral Uptake/Efflux and 
Canalicular Secretion 
TKO and dietary phytol differentially impacted hepatic expression of proteins involved in 
hepatic cholesterol uptake and loss. 
TKO did not alter hepatic levels of scavenger receptor B1 (SR-B1) or low-density 
lipoprotein receptor (LDL-R), the key receptors in bidirectional uptake/efflux of high density 
lipoprotein (HDL) cholesterol and low-density lipoprotein (LDL) cholesterol (Chapter 3 Fig. 9C, 
D), or apoA1, involved in hepatic cholesterol secretion to nascent-HDL (Chapter 3 Fig. 9A) at the 
basolateral membrane.  In contrast, TKO markedly decreased hepatic accumulation of apoB, the 
key apoprotein in LDL (Chapter 3 Fig. 9B). Concomitantly, TKO did not affect expression of ATP 
binding cassette proteins localized in the canalicular membrane for transporting hepatic cholesterol 
into bile, i.e. Abcg5, Abcg8 (Chapter 3 Fig. 9E,F).  A low level of apoB in the liver was reflected 
by high levels of apoB in the serum in TKO mice.  
Bile Acid and Transport 
 Since bile acid level in large part drives biliary cholesterol secretion (1-3), hepatic 
expression of proteins involved in bile acid reuptake from serum (Oatp1, Oatp2, Ntcp), bile acid 
cytosolic transport (FABP1, SCP2, 3αHSD, GST), and biliary secretion  of bile acid (BSEP) and 
phospholipid (MDR) at the canalicular membrane was examined.   
With regards to basolateral proteins in bile acid uptake from serum, TKO significantly 
decreased hepatic expression of Oatp1 (Chapter 3 Fig. 10A), but increased that of Oatp2 (Chapter 
3 Fig. 10B) and Ntcp (Chapter 3 Fig. 10A,C).  TKO decreased expression of the nuclear regulatory 
protein FxR, but did not affect the nuclear regulatory protein LxR (Chapter 3 Fig. 10H,I). These 
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proteins are responsible for regulating transcription of target genes in bile acid metabolism and 
uptake.  
Regarding cytosolic bile acid binding/transport proteins, TKO abolished expression of the 
major murine cytosolic bile acid binding/transport protein FABP1 (Chapter 3 Fig. 11A), and this 
null effect was not compensated for by upregulation of the other known cytosolic bile acid 
binding/transport proteins (3αHSD, GST, Chapter 3 Fig. 10D-E).  
With regards to canalicular membrane proteins involved in hepatic bile acid export into 
bile, TKO did not affect expression of the bile salt export protein BSEP (Chapter 3 Fig. 10H) or 
the canalicular membrane protein for phospholipid transport into bile (MDR, Chapter 3 Fig. 10G).   
Other Fatty Acid Binding and Transport Proteins 
The possibility of potential compensatory upregulation of other fatty acid and cholesterol 
binding proteins occurred in response to loss of FABP1 and SCP2/SCPx (TKO) was examined. 
As expected, TKO alone resulted in complete loss of FABP1 (Chapter 3 Fig. 11A) as well as all 
SCP2/SCPx gene products, SCP2 (Chapter 3 Fig. 11B), SCPx (58kDa) (Chapter 3 Fig. 6G), and 
SCPx (43kDa) (Chapter 3 Fig. 6H). These ablations resulted in compensatory upregulation of 
other known FABP family members including I-FABP (Chapter 3 Fig. 11D) and A-FABP 
(Chapter 3 Fig. 11F) with no compensatory upregulation of B-FABP (Chapter 3 Fig. 11E) or 
CRABP1 (Chapter 3 Fig. 11G).   
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CHAPTER IV 
HIGH FAT STUDY RESULTS4 
Whole Body Phenotype: Impact of Sex and TKO in High Fat Fed Mice  
Singly ablating Fabp1 increases weight gain (1-3) while singly ablating  Scp2/Scpx 
decreases weight gain  (4) in a sexually dimorphic manner.  Since singly ablating these genes 
concomitantly upregulates expression of the non-ablated gene in a sex-dependent manner, it was 
important to determine the impact of ablating both genes on whole body phenotype in both male 
and female mice on a high fat diet (HFD).  
Although wild-type (WT) male mice ate more food than WT females, TKO did not 
significantly impact total food consumed by either males or females (Chapter 4 Table 1).  
Consistent with greater food intake, WT male mice gained more total body weight than WT 
female mice, but TKO had no effect on either males or females. Furthermore, when total body 
weight was calculated on the basis of total high fat food consumed, WT males converted more of 
this increased high fat food intake to weight gain than WT females. But again, TKO did not alter 
total weight gain/total high fat food consumed (Chapter 4 Table 1). Male WT mice gained 
approximately 2-fold more than female WT mice on both HFD and control diet when measuring 
total body weight gain per high fat diet consumed in kcal. While the male TKO mice body 
weight gain/total HFD consumed was much higher than the female TKO, both the male and 
female TKO mice body weight gain/total HFD consumed was comparable to that of their WT 
mice counterparts. Also, the male and female TKO mice on control diet had similar increases in 
                                                 
4Reprinted from Milligan S, Martin GG, Landrock D, et al. Ablating both Fabp1 and Scp2/scpx (TKO) induces 
hepatic phospholipid and cholesterol accumulation in high fat-fed mice. Biochim Biophys Acta. 2018;1863(3):323-
338. doi: S1388-1981(18)30004-0 [pii]. 2018 
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total body weight gain/total control diet consumed.  Unlike the male TKO mice, the female TKO 
mice exhibited no increase resulting from HFD as compared to control diet.  
PIXImus dual-energy x-ray absorptiometry (DEXA) scans were performed to determine 
if any difference in weight gain was due to selective loss of lean tissue mass (LTM) or fat tissue 
mass (FTM) as described in Methods. Both male and female WT mice on HFD gained 
significantly more FTM as compared to their counterparts on control diet.  The male TKO mice 
also gained significantly more on HFD vs control diet but not so for the female TKO mice. WT 
males had greater weight gain as FTM than their female WT counterparts (Chapter 4 Table 1). 
TKO on HFD did not alter the relative proportion of LTM vs FTM in either male or female mice. 
Final liver weight (grams wet weight) of WT male mice was significantly greater than 
that of WT females, but was not associated with greater protein content of the liver (Chapter 4 
Table 2). TKO did not significantly alter total liver weight or liver protein content of either males 
or females.  Finally, when data were expressed as liver weight/body weight, the parameter was 
not significantly altered by either sex or TKO (Chapter 4 Table 2).  
Effect of Sex and TKO on Clinical and Morphological Hepatic Pathology 
Both WT and TKO male mice had higher levels of lipid accumulation in the liver both 
grossly and histologically where females did not show evidence of lipid accumulation (Chapter 4 
Fig. 1 and 2). TKO did not affect Kupffer cell density or size and there was no other histologic 
evidence of diffuse inflammation in the liver of WT or TKO mice. In both WT and KO mice 
there were a few very small scattered foci of inflammation which are a common incidental 
background finding in the liver of mice of all ages (5). These foci were slightly more frequent in 
TKO mice which may explain the slightly higher ALT and AST in TKO mice (Chapter 4 Table 
3).  Although AST and ALT were slightly increased in TKO mice the levels were still in the 
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normal range for mice (less than 150 and 400 units/l, respectively (blood chemistry and 
hematology in 8 inbred strains of mice, MPD:Eumorphia. Mouse Phenome Database web site, 
The Jackson Laboratory, Bar Harbor, Maine USA. http://phenome.jax.org [Cited 29 Oct, 2014]) 
(Chapter 4 Table 3).  
Effect of Sex and TKO on Hepatic Accumulation of Glyceride Lipids in High Fat Fed Mice 
  Total liver lipid levels were higher in HFD-fed WT male than WT female mice (Chapter 4 
Fig. 3A) which was associated with increased hepatic lipid accumulation both grossly and 
histologically and higher levels of phospholipid in WT males than WT females, albeit not 
significantly (Chapter 4 Fig. 3C). WT males also showed a two-fold increase in expression of the 
key enzymes in the synthesis of phosphatidic acid (precursor of both phospholipids and 
triacylglycerols), i.e. GPAT (Chapter 4 Fig 3E) and AGPAT (Chapter 4 Fig 3F).  Expression of 
Lipin 2, a key enzyme in converting phosphatidic acid to diacylglycerol for the synthesis of 
phospholipids (phosphatidylcholine, phosphatidylethanolamine) was higher in WT males than 
WT females (Chapter 4 Fig. 3H) also. However, the lack of difference in expression of DGAT 
(which transacylates diglyceride to form triglyceride) between the WT male and WT female 
groups (Chapter 4 Fig. 3G) was consistent with no significant difference in liver triacylglycerol 
levels between WT male and WT female mice (Chapter 4 Fig. 3D). Finally, it is important to 
note that despite the fact that SREBP1 was actually lower in WT male than WT female livers 
(Chapter 4 Fig. 4A), liver expression of SREBP1 target enzymes FASN (Chapter 4 Fig. 4C) and 
ACC1, the rate limiting enzyme of de novo fatty acid synthesis, did not differ between the two 
sexes in WT mice (Chapter 4 Fig. 4B). 
TKO significantly increased hepatic total lipid levels in males and females (Chapter 4 
Fig. 3A), due primarily to higher levels of phospholipid (Chapter 4 Fig. 3C) while levels of 
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neutral lipids (Chapter 4 Fig. 3B), especially triacylglycerol (Chapter 4 Fig. 3D) were not altered 
in either sex. TKO induced increases in hepatic phospholipid in male mice was associated with 
increased expression of SREBP1 (Chapter 4 Fig. 4A) despite no change in SREBP1 target 
enzymes ACC1 (Chapter 4 Fig. 4B) and FASN (Chapter 4 Fig. 4C). However, higher liver level 
of phospholipid in female TKO mice was attributed to increases in expression of enzymes in 
phospholipid synthesis [GPAT (Chapter 4 Fig 3E), AGPAT (Chapter 4 Fig 3F), Lipin 2 (Chapter 
4 Fig. 3H)] as well as increased SREBP1 (Chapter 4 Fig. 4A) and its target enzymes in de novo 
fatty acid synthesis, i.e., ACC1 (Chapter 4 Fig. 4B) and FASN (Chapter 4 Fig. 4C). 
Taken together, these findings indicate the presence of significant sexual dimorphism in hepatic 
accumulation of lipids in HFD fed mice.  Nevertheless, TKO induced hepatic accumulation of 
phospholipid in both sexes with increases in phospholipid synthetic enzymes in female high fat 
fed mice.  
Effect of Sex and TKO on Hepatic Fatty Acid Oxidation in High Fat Fed Mice 
 Decreased hepatic fatty acid oxidation may also contribute to hepatic accumulation of 
lipids. The gene products of both the Fabp1 (2, 6) and Scp2/Scpx (4, 7, 8) genes facilitate fatty 
acid uptake/oxidation. Therefore, it was important to consider potential contributions from loss 
of both FABP1 as well as SCP2/SCPx that may have reduced hepatic fatty acid oxidation to 
thereby contribute to hepatic accumulation of lipids.  This possibility was tested by examining 
serum levels of non-esterified fatty acids and β-hydroxybutyrate (β-HOB), a physiological 
measure of fatty acid oxidation, as well as determining hepatic expression of key receptors and 
enzymes involved in fatty acid oxidation in HFD fed mice.   
Although serum levels of NEFA (Chapter 4 Fig. 5A) were higher in WT males than 
females, serum levels of β-HOB (Chapter 4 Fig. 5B) did not differ between the WT male and 
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WT female mice. Similarly, serum glucose (Chapter 4 Fig. 5C), another oxidative substrate was 
higher in males than females.  This change was despite the fact that WT males had higher hepatic 
expression of fatty acid oxidative enzymes, i.e. CPT1A (Chapter 4 Fig. 5D), CPT2 (Chapter 4 
Fig. 5E), and ACOX1 (Chapter 4 Fig. 5F). Nuclear receptors involved in fatty acid oxidation 
were also measured where PPARα (Chapter 4 Fig. 5G) was higher in WT males than females but 
RXRα was lower in WT males than WT females (Chapter 4 Fig. 5H).  
TKO significantly reduced serum β-HOB (Chapter 4 Fig. 5B) in males while TKO had 
no effect on serum glucose (Chapter 4 Fig. 5C) in neither males nor females.  Decreases in serum 
β-HOB in TKO males were associated with loss of FABP1 and SCP2/SCPx and reduced 
expression of the FABP1 target nuclear receptor PPARα (Chapter 4 Fig. 5G) with no effect on 
the FABP1 target proteins CPT1A (Chapter 4 Fig. 5D), CPT2 (Chapter 4 Fig. 5E) or ACOX1 
(Chapter 4 Fig. 5F). For TKO females the unaltered NEFA (Chapter 4 Fig. 5A) and β-HOB 
(Chapter 4 Fig. 5B) was associated with potentially offsetting increases in expression of several 
FABP1 target proteins [CPT1A (Chapter 4 Fig. 5D) and CPT2 (Chapter 4 Fig. 5E)], while RXRα 
(Chapter 4 Fig. 5H) was decreased compared to WT females. 
Taken together, these data suggested that the greater lipid accumulation in HFD fed WT 
males than WT females was not associated with reduced fatty acid oxidation. However, TKO 
motivated hepatic lipid accumulation through downregulation of the FABP1 targeted nuclear 
receptors involved in the regulation of peroxisomal beta-oxidation, PPARα and RXRα, in males 
and females, respectively.  
Impact of Sex and TKO on Hepatic Cholesterol Accumulation in High Fat Fed Mice 
Both Fabp1  (9-11) and Scp2/Scpx (12-15) gene products bind, enhance uptake, facilitate 
metabolism, and function in removal of cholesterol from the liver into bile.  Therefore, the 
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impact of sex and TKO on the hepatic accumulation of cholesterol was determined in HFD fed 
mice. 
Hepatic cholesterol levels were markedly sex-dependent and impacted by TKO. The 
hepatic level of total cholesterol was significantly higher in WT male than WT female mice 
(Chapter 4 Fig. 6A), due primarily to increased free cholesterol (Chapter 4 Fig. 6B) at the 
expense of cholesteryl ester (Chapter 4 Fig. 6C). The higher liver cholesterol level in WT males 
was associated with higher levels of SREBP2 (Chapter 4 Fig. 6D) despite WT females 
expressing higher levels of SREBP2 target proteins in de novo cholesterol synthesis, i.e.  
HMGCS1 (Chapter 4 Fig. 6E) and HMGCR (Chapter 4 Fig. 6F). Hepatic expression of enzymes 
in cholesterol esterification, i.e. ACAT2 (Chapter 4 Fig. 6G) and hydrolysis, i.e. HSL (Chapter 4 
Fig. 6H) did not account for the hepatic cholesterol accumulation in WT males.   
TKO markedly increased hepatic total cholesterol accumulation in females but not males 
(Chapter 4 Fig. 6A). Increased total cholesterol in TKO females was attributed to increases in 
both hepatic free cholesterol (Chapter 4 Fig. 6B) and cholesteryl ester (Chapter 4 Fig. 6C). 
Though males did not experience an increase in total cholesterol, TKO significantly increased 
cholesteryl ester accumulation (Chapter 4 Fig. 6C). Despite increases in hepatic cholesterol in 
females, there was no significant change in hepatic level of SREBP2 (Chapter 4 Fig. 6D) as well 
as no change in expression of HMGCS1 (Chapter 4 Fig. 6E) and HMGCR (Chapter 4 Fig. 6F). 
Again, altered hepatic expression of enzymes in cholesterol esterification, i.e. ACAT2 (Chapter 4 
Fig. 6G) and hydrolysis, i.e. HSL (Chapter 4 Fig. 6H) in TKO mice did not account for the 
hepatic cholesterol accumulation. In contrast, expression of HSL was higher in TKO females 
than WT females.    
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In general, these data indicate that loss of Fabp1 and Scp2/Scpx gene products, rather 
than major upregulation of de novo cholesterol synthesis and esterification, contributed to 
increased hepatic cholesterol levels in HFD fed TKO mice. 
Impact of Sex and TKO on Hepatic Expression of Proteins Involved in Hepatic Uptake and 
Efflux/Secretion of Cholesterol in High Fat Fed Mice 
 FABP1 enhances the uptake of HDL-cholesterol into the cytosol (14), while SCP2 
facilitates both uptake and efflux of lipoprotein-derived cholesterol into/from the cytosol (13, 14, 
16). Therefore, it was essential to determine potential contributions of compensatory alterations 
in other proteins mediating lipoprotein cholesterol uptake/secretion/excretion in male and female 
Fabp1/Scp2/Scpx gene ablated mice fed HFD.  
Hepatic expression of SR-B1, the receptor for uptake of HDL-cholesterol, was 
significantly lower in WT male than WT female mice (Chapter 4 Fig. 7A). This decrease was 
offset in part by WT males expressing higher hepatic levels of proteins in hepatic HDL secretion, 
i.e. APOA1 (Chapter 4 Fig. 7B) and ABCG4 (Chapter 4 Fig. 7E). Concomitantly, ABCG1 
(Chapter 4 Fig. 7D), another protein involved in nascent cholesterol secretion, did not differ 
between the sexes. Liver levels of LDL-R, the receptor for the uptake of LDL-cholesterol, were 
also markedly higher in WT male than WT female mice (Chapter 4 Fig. 7F). However, again, 
this increase was offset in part by higher levels of a key hepatic protein involved in secretion of 
cholesterol as VLDL (precursor of LDL), i.e. APOB (Chapter 4 Fig. 7G). MTP, another protein 
involved in secretion of cholesterol as VLDL, was unaffected by sex. (Chapter 4 Fig. 7H).  
Despite sexual dimorphism in hepatic cholesterol accumulation, there was no difference in the 
major liver canalicular proteins involved in translocating cholesterol into bile, i.e. ABCG5 
(Chapter 4 Fig. 7I) and ABCG8 (Chapter 4 Fig. 7J), between males and females.  
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TKO did not affect hepatic level of SR-B1 in either sex (Chapter 4 Fig. 7A) but did 
increase hepatic level of several proteins involved in nascent HDL secretion including ABCG1 
(Chapter 4 Fig. 7D) and ABCG4 (Chapter 4 Fig. 7E) while significantly decreasing APOA1 
(Chapter 4 Fig. 7B) in males. Although TKO had no effect on SR-B1 in females (Chapter 4 Fig. 
7A), it differentially impacted proteins involved in nascent HDL formation by increasing 
ABCA1 (Chapter 4 Fig. 7C), and ABCG1 (Chapter 4 Fig. 7D) and decreasing ABCG4 (Chapter 
4 Fig. 7E).  TKO increased hepatic expression of ABCG5 (Chapter 4 Fig. 7I) in both males in 
females while having no impact on ABCG8 (Chapter 4 Fig. 7J). 
These data indicated that the higher hepatic cholesterol level in WT males was associated 
with higher levels of proteins in the non-HDL-cholesterol uptake pathway (LDL-R) despite the 
higher level of the key protein in nascent LDL secretion, APOB.  The TKO-induced increase in 
hepatic cholesterol in males was associated at least in part with concomitant downregulation of 
the key protein in nascent HDL secretion (APOA1). In contrast, the TKO-induced increase in 
hepatic cholesterol in females did not consistently correlate with concomitant upregulation or 
downregulation of liver proteins in HDL-cholesterol uptake/efflux, LDL-cholesterol uptake, or 
VLDL-cholesterol secretion.  
Effect of Sex and TKO on Hepatic Expression of Intracellular Proteins Involved in Cytosolic 
Transport of Cholesterol in High Fat Fed Mice 
FABP1 facilitates cytosolic transport of cholesterol to the plasma membrane for secretion 
of cholesterol as lipoprotein (1, 17), to the endoplasmic reticulum for esterification by ACAT2 
(18), or to bile canaliculi for biliary cholesterol excretion (10, 15, 19).  Similarly, SCP2 also 
facilitates cholesterol transfer from the plasma membrane to the endoplasmic reticulum (20, 21) 
for esterification by ACAT2 (22, 23), to mitochondria and peroxisomes for oxidation to steroids 
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(24, 25) or bile acids (26-28), and to bile canaliculi for biliary excretion (15, 19, 27). Thus, it was 
important to determine the effect of sex and TKO on hepatic expression of cytosolic cholesterol 
binding/transfer proteins in HFD fed mice. 
The higher hepatic cholesterol level in WT male mice was associated with WT males 
having higher levels of both FABP1, the most prevalent intracellular cholesterol 
binding/transport protein (Chapter 4 Fig. 8A) as well as SCP2 (Chapter 4 Fig 6B). However, 
hepatic levels of other less prevalent intracellular cholesterol binding proteins, GST (Chapter 4 
Fig. 8C) and 3αHSD (Chapter 4 Fig. 8D) were lower in WT males than WT females. 
TKO resulted in complete loss of FABP1 (Chapter 4 Fig. 8A) and SCP2 (Chapter 4 Fig. 
8B) in both males and females.  This loss resulted in potential partial compensatory upregulation 
of 3αHSD in males (Chapter 4 Fig. 8D) while neither GST (Chapter 4 Fig. 8C) nor 3αHSD 
(Chapter 4 Fig. 8D) were upregulated in females. 
Taken together, the finding of higher hepatic cholesterol levels in WT males than WT 
females was associated with higher levels of FABP1 and SCP2. In TKO mice, the absence of 
FABP1 and SCP2 was compensated for only in part by increased level of one less common 
cholesterol binding protein, i.e. 3αHSD, and not GST (Chapter 4 Fig. 8C, D), in males, while 
both 3αHSD (Chapter 4 Fig. 8D) and GST (Chapter 4 Fig. 8C) were decreased in females.  
Effect of Sex and TKO on Serum Lipoproteins and Apoproteins in High Fat Fed Mice.  
The findings in the preceding sections suggest potential contributions of sex and TKO to 
altering serum apoprotein and lipoprotein profile in HFD fed mice. This possibility was 
examined as described in Methods. In addition, serum apolipoprotein bound cholesterol has been 
shown to be affected by FABP1 expression, where FABP1 ablation significantly reduces serum 
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HDL cholesterol levels in mice fed a standard chow. Therefore, it was essential to examine the 
effects of ablation in mice fed a HFD diet. 
FABP1 upregulation in male WT mice contributed to higher serum levels of HDL-
cholesterol (Chapter 4 Fig. 9A) and APOA1 (Chapter 4 Fig. 9B), although the ratio of 
APOA1/HDL-cholesterol did not significantly differ between the sexes (Chapter 4 Fig. 9C). 
Higher levels of HDL-C in WT males also were associated with lower SR-B1, the hepatic 
receptor for HDL-C. Despite increased expression of LDL-R, the hepatic receptor for LDL-C, 
the serum level of non-HDL-cholesterol (Chapter 4 Fig. 9D) and APOB (Chapter 4 Fig. 9E) 
were higher in WT males, but the ratio of non-HDL-cholesterol/APOB was not significantly 
different (Chapter 4 Fig. 9F). In addition, TKO males had higher levels of serum non-HDL-C 
(Chapter 4 Fig. 9A), APOB (Chapter 4 Fig. 9 E) and APOB/non-HDL-C ratio (Chapter 4 Fig. 
9F) than TKO females. 
In male mice, TKO decreased serum levels of HDL-cholesterol (Chapter 4 Fig. 9A) and 
APOA1 (Chapter 4 Fig. 9B) without altering the ratio of APOA1/HDL-cholesterol (Chapter 4 
Fig. 9C).  While TKO decreased APOB levels in both males and females (Chapter 4 Fig. 9E), the 
level of non-HDL-cholesterol was not significantly altered (Chapter 4 Fig. 9D). Though the ratio 
of APOB/non-HDL-C was increased in TKO males, decreased APOB levels in TKO females, 
albeit not significantly, contributed to a decreased APOB/non-HDL-C ratio (Chapter 4 Fig. 9F). 
Overall, sex and TKO affected serum lipoprotein and apoprotein levels in males and 
females.  Further, higher serum HDL-C in WT males was associated with higher hepatic FABP1 
and lower hepatic SR-B1. Though LDL-R levels were increased in both WT and TKO male 
groups compared to both female groups, non-HDL-C levels only differed between TKO males 
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and females. These data confirm that Fabp1/Scp2/Scpx gene ablation yields a sexually dimorphic 
response in serum apolipoproteins involved in serum cholesterol transport. 
Impact of Sex and TKO on Hepatic Proteins involved in Biliary Bile Formation in High Fat Fed 
Mice 
Bile acid production and canalicular excretion drives co-secretion of cholesterol into bile 
to regulate hepatic cholesterol level.  FABP1 binds bile acids (9, 10, 29, 30) and enhances 
transfer/targeting of HDL-derived cholesterol (and cholesteryl ester after hydrolysis) to the bile 
canaliculus for biliary excretion (10, 15, 19).  SCP2 enhances cholesterol transfer to 
mitochondria and peroxisomes for oxidation to bile acids [30,54,81] and to the bile canaliculus 
for cholesterol biliary excretion (15, 19, 27). Therefore, the impact of sex and TKO on hepatic 
expression of proteins involved in bile acid production and dynamics was determined in HFD fed 
mice. 
Hepatic levels of bile acids were significantly higher in WT males than WT females 
(Chapter 4 Fig. 10A) which was associated with decreased levels in the expression of the rate 
limiting enzyme in hepatic bile acid synthesis, i.e. CYP7A1 (Chapter 4 Fig. 10B), as bile acids 
repress the transcription of CYP7A1. Higher hepatic bile acids were also associated with higher 
levels of hepatic proteins involved in bile acid re-uptake from the blood, i.e. OATP1 (Chapter 4 
Fig. 10C) or OATP2 (Chapter 4 Fig. 10D). However, BSEP (Chapter 4 Fig. 10F), which codes 
for a protein involved in canalicular bile acid secretion, was also higher in WT males than 
females.  Another hepatic protein in canalicular bile acid secretion into bile, MDR2 (Chapter 4 
Fig. 10G) along with hepatic proteins in cytosolic phosphatidylcholine transport and canalicular 
secretion into bile, i.e. MRP2 (Chapter 4 Fig. 10E) and PCTP (Chapter 4 Fig. 10H) remained 
unchanged between WT males and females.  
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Though expression of CYP7A1 in WT males was less than females, levels of the nuclear 
regulatory protein that contributes to hepatic cholesterol homeostasis by upregulating CYP7A1 
in the presence of high cholesterol, i.e. LXR (Chapter 4 Fig. 11A), was higher in WT males than 
females. This also held true for TKO males compared to TKO females. WT males also expressed 
higher levels of a nuclear regulatory protein involved in downregulating the import and synthesis 
of bile acids, i.e. SHP (Chapter 4 Fig. 11C). FXR, which induces SHP (31) was not affected by 
sex in WT mice (Chapter 4 Fig 9. B).  
TKO had little effect on hepatic bile acid levels in either male or female mice (Chapter 4 
Fig. 10A). While complete loss of key proteins involved in bile acid formation, binding, and 
cytosolic transport (FABP1, SCP2, SCPx), was expected to lower liver bile acid levels, 
concomitant upregulation of the key synthetic enzyme (CYP7A1, Chapter 4 Fig. 10B) in males, 
and apical proteins in bile acid reuptake from serum, i.e. OATP1 (Chapter 4 Fig. 10C), OATP2 
(Chapter 4 Fig. 10D) and MRP2 (Chapter 4 Fig. 10F) in both sexes, apparently compensated to 
maintain liver bile acid levels. This was in spite of a TKO induced upregulation of a major 
canalicular bile acid export pump (BSEP, Chapter 4 Fig. 10E) while another canalicular bile acid 
pump was not affected (MDR, Chapter 4 Fig. 10H). TKO induced upregulation of SHP in both 
males and females compared to their WT counterparts (Chapter 4 Fig. 11C) but did not impact 
hepatic expression of other nuclear receptors regulating transcription of proteins in bile acid 
synthesis in either males or females (Chapter 4 Fig. 11A-B). 
Taken together, these findings suggested that HFD fed WT males’ higher liver bile acid 
level was associated with greater reuptake despite increased BSEP, involved in canalicular bile 
acid secretion. TKO did not alter hepatic bile acid levels largely due to compensatory 
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upregulation of the rate limiting bile acid synthetic enzyme in males and of apical transporters 
for bile acid reuptake in both sexes. 
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CHAPTER V 
PHYTOL STUDY CONCLUSIONS AND DISCUSSION5 
Since accumulation of branched-chain fatty acids derived from dietary phytol is toxic (1, 
2), most research has focused on identification of the individual peroxisomal enzymes in their 
metabolism and the pathological consequences of genetic mutations therein (3-7). In contrast, 
much less is known about how these poorly soluble branched-chain lipids traffic through the 
hepatocyte cytosol for metabolism. In vitro ligand binding (8-11) and transfected cell (8-10, 12) 
studies suggest FABP1 and SCP2/SCPx gene products act as potential ‘chaperones’. Further, a 
highly prevalent human FABP1 SNP (26-38% allele frequency) (13-19) resulting in FABP1 
T94A substitution alters uptake/metabolism of another branched-chain lipid, cholesterol (14, 18, 
20, 21). Human subjects expressing the FABP1 T94A variant exhibit marked triglyceride 
accumulation in liver (18, 20), elevated triglyceride and LDL cholesterol in serum (14, 22, 23), 
and increased incidence of cardiovascular disease (14, 16, 22). Although less prevalent, a 
mutation in the human SCPx gene completely abolishes SCPx activity, markedly elevates serum 
levels of branched chain fatty acids (phytanic acid, pristanic acid), and induces 
neurodegeneration (24, 25). While gene-targeted mice ablated in FABP1 (10, 26-31), SCPx (32), 
or SCP2/SCPx  (33-37) have proven useful in resolving respective physiological roles, 
concomitant upregulation of the non-ablated chaperone, especially FABP1 in  SCP2/SCPx null 
or SCPx null mice, complicates interpretation of phenotype (32, 35, 36). The current study with 
                                                 
5Milligan S, Martin GG, Landrock D, et al. Ablating both Fabp1 and Scp2/scpx (TKO) induces hepatic phospholipid 
and cholesterol accumulation in high fat-fed mice. Biochim Biophys Acta. 2018;1863(3):323-338. doi: S1388-
1981(18)30004-0 [pii]. 
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mice ablated in both SCP2/SCPx and FABP1 genes (SCP2/SCPx/FABP1 triple gene ablation or 
TKO) provided several important insights: 
First, ablating both FABP1 and SCP2/SCPx significantly affected whole body phenotype 
in mice fed a high phytol diet as compared to ablating each individually. In earlier findings, 
feeding dietary phytol alone decreased body weight of female wild-type (WT) mice (38), an 
effect not further exacerbated upon ablating FABP1 (26).  In contrast, singly ablating SCPx or 
SCP2-SCPx markedly exacerbated phytol diet-induced weight loss several-fold  (32, 35). 
Likewise, ablating FABP1 in SCP2/SCPx null mice (i.e. TKO) nearly doubled the dietary 
phytol-induced weight loss, an effect attributed to both decreased food consumption and energy 
intake. These data indicated that concomitant upregulation of FABP1 in SCP2/SCPx null or 
SCPx null mice (32, 35, 36, 39) did not diminished and/or obscure the impact of SCP2/SCPx 
ablation on dietary phytol-induced weight loss. This outcome suggests that SCP2/SCPx may play 
a greater role than FABP1 in exacerbating phytol-induced weight loss.  
Second, the TKO data presented herein suggested that SCP2/SCPx gene products, much 
more than the FABP1, contributed to phytol oxidation. In response to dietary phytol, 
peroxisomal oxidation products of phytanic acid and pristanic acid accumulate concomitant with 
upregulation of FABP1, SCP2, SCPx and peroxisomal oxidative enzymes in WT mice (38).  
FABP1 gene ablation did not further exacerbate this dietary phytol-induced increase likely due to 
concomitant upregulation of SCPx, a key peroxisomal enzyme in phytol oxidation (26).  In 
contrast, singly ablating SCPx or SCP2-SCPx markedly decreased dietary phytol-induced 
accumulation of phytol metabolites despite concomitant upregulation of FABP1 (32, 35, 36, 39) 
and some fatty acid oxidative enzymes (32, 35). Ablating FABP1 in SCP2/SCPx null mice (i.e. 
TKO) did not further exacerbate dietary-phytol induced oxidation and upregulation of fatty acid 
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oxidative enzymes. These findings suggested that SCP2/SCPx gene products may play a greater 
role in phytol oxidation than FABP1.  Consistent with this possibility, nearly half of SCP2 is 
peroxisomal, while all of SCPx is peroxisomal and SCPx is the only known peroxisomal 
ketoacyl-CoA thiolase involved in branched chain fatty acid oxidation (40). Despite these 
findings, however, FABP1 may serve a lesser role in phytol metabolism, i.e. in re-uptake of 
excess phytol metabolites from serum (10). FABP1 enhances fatty acid uptake (41-43), accounts 
for 80-90% of hepatic cytosol binding/transport capacity for fatty acids and fatty acyl-CoAs (44, 
45), and is the most prevalent cytosolic transporter for targeting these ligands to mitochondria 
and peroxisomes for oxidation  (37, 46, 47). Loss of FABP1 alone decreases hepatocyte uptake 
of phytanic acid (10). In contrast, ablation of SCP2/SCPx significantly decreases serum NEFA, 
attributable in large part to marked upregulation of FABP1 (35, 39).  TKO offset the effect of 
FABP1 upregulation in SCP2/SCPx ablated mice since serum NEFA levels were unaltered. 
Taken together, these findings suggested that in the context of high dietary phytol, SCP2/SCPx 
has a greater role in oxidation while FABP1 may have a role in reuptake.  
Third, TKO markedly increased hepatic lipid accumulation, primarily due to increased 
phospholipid, in phytol-fed female mice. Earlier it was shown that dietary phytol alone increased 
hepatic lipid accumulation, primarily by increasing phospholipid in female wild-type (WT) mice 
(38),  an effect exacerbated upon FABP1 ablation (26).  FABP1 is known to stimulate the rate 
limiting enzyme in phospholipid synthesis (GPAT) in vitro (48-50). FABP1 overexpression in 
transfected cells increases fatty acid uptake and incorporation into triglyceride, albeit 
quantitatively not as much as into phospholipid (41). In contrast, singly ablating SCPx or SCP2-
SCPx decreased hepatic total lipid, primarily by decreasing triglyceride (32, 35) concomitant 
with upregulation of FABP1 (32, 35, 36, 39). Ablating FABP1 in SCP2/SCPx mice (i.e. TKO) 
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fed phytol mice reflected a combined phenotype where phospholipid was increased nearly 5-fold 
at the expense of triglyceride.  The increased hepatic phospholipid was associated with increased 
transcription of the rate limiting gene in de novo fatty acid synthesis (Acc1) and enzymes in 
phospholipid synthesis (Gpam, Agpat). Taken together, these findings suggested that in the 
context of phytol-diet, FABP1 and SCP2/SCPx play somewhat different roles in hepatic lipid 
accumulation, differing in preferentially impacting phospholipid versus triglyceride.  
Fourth, phytol diet TKO increased cholesterol in the serum, but not liver. Dietary phytol 
alone did not alter hepatic cholesterol accumulation in female wild-type (WT) mice (26).  
However, FABP1 gene ablation significantly increased only hepatic free cholesterol, but not 
cholesteryl ester or total cholesterol, in phytol-fed females (26).  Likewise, singly ablating SCPx 
did not significantly alter hepatic total, free, or esterified cholesterol in female mice (32) while 
ablating SCP2/SCPx increased hepatic total and esterified cholesterol level (39)—effects likely 
attributed to concomitant greater upregulation of FABP1 (32, 35, 36, 39). FABP1 overexpression 
in cultured cells enhances cholesterol uptake and intracellular targeting for esterification (51, 52). 
Concomitant FABP1 upregulation in SCP2 overexpression mice also induces hepatic cholesterol 
accumulation (53-55). Taken together, these data suggested that FABP1 upregulation may 
counteract the effect of ablating SCP2/SCPx or SCPx on hepatic cholesterol.  
In summary, the results presented herein with TKO mice shed significant new insights 
into the roles of FABP1 and SCP2/SCPx genes in whole body weight gain and hepatic lipid 
metabolism in response to dietary phytol. TKO exacerbated dietary phytol-induced whole-body 
weight loss, especially lean tissue mass (LTM). TKO also increased hepatic total lipid 
accumulation, primarily phospholipid, in response to upregulation of hepatic levels of proteins in 
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the phospholipid synthesis. Increased hepatic lipid accumulation was not attributable to any 
concomitant upregulation of membrane fatty acid transport/translocase proteins involved in fatty 
acid uptake (FATP2, FATP4, FATP5 or GOT) or cytosolic proteins involved in fatty acid 
intracellular targeting (ACBP). Since individually ablating SCPx or SCP2/SCPx elicited 
concomitant upregulation of FABP1, these findings with TKO mice significantly contribute to 
our understanding of the respective roles of these genes in dietary phytol metabolism.    
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CHAPTER VI 
HIGH FAT STUDY CONCLUSIONS AND DISCUSSION6 
Although singly ablating Fabp1 or Scp2/Scpx genes may exacerbate the impact of HFD 
on whole body phenotype and hepatic lipid metabolism, dietary regimen (mice prefer and 
consume more ad libitum fed HFD), sex-differences, and/or concomitant upregulation of the 
non-ablated gene complicate interpretation of such findings.  This is especially evident in mice 
singly ablated in Scp2/Scpx or Scpx wherein hepatic levels of FABP1 are concomitantly 
upregulated (1,2,3).  To further resolve the impact of Scp2/Scpx gene ablation on whole body and 
hepatic phenotype independent of FABP1 upregulation, the current study was undertaken by 
examining the impact of also ablating Fabp1 in Scp2/Scpx null mice (i.e. Fabp1/Scp2/Scpx 
ablation or TKO). In order to preclude potential complications of data interpretation, these 
studies were performed by: i) pair-feeding high fat diet (HFD) independent of increased 
preference and intake of HFD (rev. in (4) and ii) phytoestrogen-free and phytol-free HFD 
independent of potential estrogenic (5,6) or PPARα (7,8,9) induction effects of these lipophilic 
molecules. The data provided the following new insights on the impact of these genes on whole 
body and liver lipid phenotype in both male and female mice pair-fed HFD.  
First, female WT mice consumed more total high fat diet as percent of body weight than 
their male WT counterparts, but the WT male mice gained significantly more body weight than 
female WT mice.  The study herein continued from 8 weeks to 20 weeks. Studies involving 
C57BL/6 mice examining various high fat diets, demonstrate various weight gains for male vs 
                                                 
6Milligan S, Martin GG, Landrock D, et al. Impact of dietary phytol on lipid metabolism in SCP2/SCPX/L-FABP 
null mice. Biochim Biophys Acta. 2017;1862(3):291-304. doi: S1388-1981(16)30328-6 [pii].  
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female mice.  It is difficult to compare each study due to the different starting ages, substrains, 
duration, diet compositions, and microbiota.  In one particular study wherein C57BL/6N mice 
were put on a HFD at 4 weeks of age, females gained similar weight to males until about after 16 
weeks duration and overtook the males in body weight after about 30 week duration  (10). 
However another HFD study involving C56BL/6J mice beginning at 3 weeks (after weaning) 
and lasting until the mice were 9 months, showed the male WT on HFD continuing to gain 
weight at a similar or slightly higher rate (11). Further, while the male mice outdistanced their 
counterparts on normal diet throughout, the female mice on HFD were similar to their 
counterparts on normal diet up to about 4 months of age (11). A different study involving 
C57BL/6J mice revealed that the fatty acid profile of HFD was linked to sex differences in 
weight gain (12). Further complicating direct comparisons, the C57BL/6J substrain is more 
sensitive to high fat diet-induced obesity than the C57BL/6N substrain (13). 
In comparing total body weight gain per high fat diet consumed in kcal, the male WT 
mice gained approximately 2-fold more than female WT mice. The 2-fold increase was similar to 
the WT male vs female gain on control diet. In contrast, the TKO male vs female mice on control 
diet did not differ in total body weight gain per total food consumed on control diet. While the 
female TKO mice exhibited no increase as compared to control diet, the male TKO mice 
significantly gained more than the male WT mice on the control diet—comparable to that of the 
WT male mice on HFD.  
The body weight gain exhibited by the male WT vs female WT mice was associated with 
increased hepatic levels of the two major cytosolic long chain fatty acid (LCFA) and LCFA-CoA 
binding proteins, i.e. FABP1 and SCP2.  Even in the context of control-chow fed diets, hepatic 
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protein levels of FABP1, SCP2 and SCPx are also higher in livers of male than female mice  (14, 
15, 16, 17).  
Second, male WT mice exhibited greater hepatic lipid accumulation than their female 
counterparts fed the same HFD.  While FABP1 stimulates both anabolic and catabolic aspects of 
LCFA metabolism, in the context of HFD the net effect of the anabolic processes appeared 
greater in WT male than WT female mice.  The WT male mice’s greater hepatic lipid 
accumulation was associated directly with:  i) Higher hepatic levels of FABP1 and SCP2. 
FABP1 is known to enhance uptake (18-22) and cytosolic transport of exogenous LCFA (18, 23, 
20) for anabolic processes such as esterification in the endoplasmic reticulum (ER) (24-26), and 
lipoprotein budding from ER for secretion (27, 28).  Likewise, SCP2 also enhances uptake of 
LCFA and cholesterol (29, 30), LCFA cytosolic transport (30), and esterification in the 
endoplasmic reticulum  (31-34) ; ii) Higher hepatic expression of several key enzymes in the 
synthesis of phospholipids (GPAT, AGPAT, and Lipin 2).  In contrast, over all, LCFA 
catabolism was not higher in HFD-fed WT males than females.  Consistent with the higher 
hepatic expression of FABP1 and SCP2 in HFD-fed WT males than females, hepatic expression 
of LCFA oxidative enzymes was higher in HFD-fed WT males than females (CPT1A, CPT2, and 
ACOX1). FABP1 facilitates LCFA/LCFA-CoA targeting for oxidation in mitochondria and 
peroxisomes (18, 35) as well as targeting to nuclei for LCFA and LCFA-CoA activating PPARα 
transcription of oxidative enzymes (36, 37). SCP2 also enhances LCFA oxidation (38).  
Nevertheless, the HFD-fed WT male and female mice did not differ in LCFA oxidation as 
indicated by unaltered serum β-HOB levels. This suggested that in the context of HFD, the 
higher levels of FABP1 and SCP2 in WT males than females resulted in preferential targeting of 
LCFA towards anabolic metabolism (i.e. lipid synthesis and storage). Consistent with this 
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possibility, the greater body weight gain of HFD-fed WT males was associated with 5-fold 
greater gain as FTM as well as LTM as compared to females.   
Third, while TKO male mice had less weight gain than WT mice on control diet, the 
TKO had little effect on whole body phenotype in either male or female HFD-fed mice as 
compared to their WT counterparts. Singly ablating the Fabp1 gene increases whole body weight 
gain in females and less so in males (39-42). Conversely, singly ablating the Scp2/Scpx gene 
decreases body weight, especially in females (3, 17).Taken together, these findings suggested 
that the reduced whole body weight of Scp2/Scpx gene ablated mice was not attributable to 
concomitant upregulation of FABP1.  The two genes appeared to impact oppositely the whole 
body weight gain in HFD fed mice. 
Fourth, TKO significantly increased hepatic accumulation of lipid (phospholipid, 
cholesterol, cholesteryl ester) in both male and female HFD-fed mice. Despite the loss of both 
FABP1 and SCP2, three factors contributed to increased hepatic lipid accumulation. They 
include the following:  i) Upregulation of other cytosolic lipid ligand (LCFA, cholesterol) 
‘chaperone’ proteins (3αHSD) in TKO males but not females; ii) Upregulation of key proteins in 
phospholipid synthesis (GPAT, AGPAT, and/or Lipin 2) in females and de novo LCFA synthesis 
(SREBP1 in males and females; ACC1 and  FASN in females). Singly ablating Fabp1 decreased 
hepatic triacylglycerol in males while increasing phospholipid, cholesterol and cholesteryl ester 
in females (43).  Despite concomitant upregulation of FABP1, singly ablating Scp2/Scpx 
increased hepatic accumulation of lipid (phospholipid, triacylglycerol, cholesteryl ester) in both 
male and female mice (17). Taken together, these data indicated that FABP1 and SCP2/SCPx 
had a greater impact on hepatic triacylglycerol and cholesterol, respectively, but in a sex 
dependent manner; iii) Decreased LCFA oxidation as indicated by decreased serum β-HOB in 
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male mice. Despite downregulation of hepatic expression of nuclear receptors regulating 
expression of LCFA oxidative enzymes in both males and females (PPARα and RXRα, 
respectively), expression of several LCFA oxidative enzymes (CPT1A, CPT2) was upregulated 
in TKO females but not males.  Singly ablating Fabp1 reduced LCFA oxidation as well as 
ligand-induced PPARα transcription of LCFA oxidative enzymes (18, 19, 39, 44-46). Despite 
concomitant upregulation of FABP1, singly ablating Scp2/Scpx also decreased LCFA oxidation 
(3).  Again, these findings suggested that SCP2/SCPx may have a greater impact on LCFA 
oxidation than FABP1.  
Fifth, sex, more than Fabp1/Scp2/Scpx gene ablation, played a significant role in hepatic 
bile acid synthesis, reuptake and secretion. WT male mice exhibited higher levels of hepatic bile 
acid with concomitant downregulation of CYP7A1 expression compared to WT females. WT 
males also exhibited increased proteins involved in the reuptake of bile acid from serum (OATP1 
and OATP2) despite increases in BSEP and SHP which are involved in the secretion and 
decreased synthesis of bile acids, respectively. FABP1 and SCP2/SCPx have been shown to play 
distinct, but complimentary roles in hepatic bile acid homeostasis where FABP1 is involved in 
the retention of bile acids and SCP2/SCPx functions in the formation and biliary secretion of bile 
acids. These findings suggest that the increase in hepatic bile acid concentration in WT mice was 
impacted by upregulation of FABP1 and SCP2 and specifically, their bile acid retention and 
formation functions.  Again, TKO had no effect on hepatic bile acid levels. This was due to the 
concomitant upregulation of bile acid synthetic and reuptake proteins (CYP7A1, OATP1, 
OATP2) and contrasting upregulation of proteins involved in inhibiting the synthesis and 
promoting the canalicular secretion of bile acids (SHP, MRP2 and BSEP).    
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Sixth and finally, ablation of Scp2/Scpx in Fabp1 null mice (TKO) impacted hepatic 
phospholipid mass to a greater extent than ablating Fabp1 alone—especially in the context of 
HFD. For example, in HFD-fed mice TKO significantly increased liver phospholipid mass in 
both males and females (shown herein)—in marked contrast to LKO alone which did not alter 
hepatic phospholipid level in either sex (47). However, in control-fed mice, TKO selectively 
increased hepatic phospholipid in females but not males (not shown)—similarly as shown for 
LKO in control-fed females vs males  (47-49, 19). In contrast, ablating only the Scp2/Scpx gene 
(DKO) alone had no effect on hepatic phospholipid content in either male or female control-fed 
mice (17).  Taken together, these findings suggest that the impact of Scp2/Scpx and Fabp1 gene 
products on hepatic phospholipid phenotype is complex, highly dependent on the expression of 
one or both these genes, and is significantly dependent on the context of sex and dietary fat. Both 
direct and indirect mechanism(s) may be involved. For example, both FABP1 and SCP2 are 
known to bind fatty acyl-CoA and directly stimulate microsomal glycerol-3-phosphate 
acyltransferase (GPAT)—the rate limiting step in synthesis of phosphatidic acid from which 
other phospholipid subclasses are derived (24, 26, 34, 50).  Whether FABP1 and/or SCP2 may 
also and possibly differentially impact other fatty acyl-CoA transacylation enzymes in the 
formation of phospholipid classes vs triacylglycerols is not known.  Alternately, FABP1 (but not 
SCP2) is known to transfer bound ligands (fatty acids, fatty acyl-CoAs, xenobiotics) through the 
cytosol, into nuclei wherein it binds to nuclear receptors (e.g. PPARα) to facilitate ligand transfer 
and activate transcription of numerous genes in fatty acid metabolism (rev. in (39, 37, 51, 52, 
53).  While the absence of FABP1 and SCP2 (i.e. TKO) would thereby normally be expected to 
reduce PPARα transcriptional activity, inhibition of phytol metabolism elicits the opposite 
response since in phytol-fed mice (54). TKO markedly inhibits phytol metabolism in phytol-fed 
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mice and induces accumulation of high levels of phytol metabolites (phytanic acid and pristanic 
acid) that are potent PPARα activators (54).  These metabolites in turn induce transcription of 
key enzymes regulating the synthesis of phosphatidic acid (Gpam, Agpat) as well as 
synthesis/hydrolysis of triacylglycerol (Lipin, Dgat) (54). Resolving whether FABP1 also either 
directly impacts enzyme activities and/or transcription of mRNAs encoding enzymes in 
phospholipid synthetic steps downstream from Gpat (e.g. Pcyt1a, Pemt, Pcyt2, Ptdss1 and 2) is 
beyond the timeframe and scope of this manuscript.  
In summary, both Fabp1 and Scp2/Scpx gene products play important roles in regulating 
whole body phenotype and hepatic lipid accumulation in mice. Hepatic FABP1 protein level is 
greatly upregulated in human NAFLD (55-57) and in animal models of NAFLD (58, 59).  
Furthermore, a highly prevalent SNP in the coding region of the human Fabp1 gene results in a 
T94A amino acid substitution (57, 60-62)  that is associated with NAFLD (57, 63). Three 
additional promising fields of research on potential roles of FABP1 (and potentially SCP2) in the 
development of NAFLD are:  i) The role of microbiome alteration in NAFLD pathogenesis.  
Studies have shown that gut dysbiosis not only leads to human obesity, but also that many 
microbial cell components resulting from gut dysbiosis contribute to hepatic inflammation and 
steatosis (64). It has also been shown that fecal transplantation from mice with NAFLD into 
healthy wild-type mice results in NAFLD in those healthy mice (65). Environmental modifiers 
such as differences in gut microbiome have been suggested to contribute to the phenotype of 
Fabp1 gene ablated mice (66). ii) The impact of FABP1 on the hepatic endocannabinoid system 
in the development of NAFLD.  Recent discoveries with Fabp1 gene ablated mice have resolved 
a link between FABP1, the endocannabinoid (EC) system and NAFLD. FABP1 is the most 
prevalent endocannabinoid and cannabinoid binding/’chaperone’ protein present in hepatic 
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cytosol of mice (16, 62). Ablation of the Fabp1 gene increased hepatic levels of AEA and 2-AG, 
endogenous agonists of the cannabinoid receptor CB1, which have been associated with NAFLD 
(16).  Although SCP2 also binds AEA and 2-AG with high affinity (16, 67, 68), Scp2/Scpx gene 
ablation decreases brain levels of endocannabinoids but concomitantly increases CB1 levels (69). 
However, nothing is known regarding the impact of ablating the Scp2/Scpx gene or SNPs therein 
on the hepatic endocannabinoid system and/or NAFLD. iii) TKO results in different metabolic 
patterns between male and female mice due to sex differences in FABP1 and SCP2/Scpx 
expression as well as to Fabp1 and Scp2/Scpx having different metabolic functions in health and 
disease.  For example, phytol (a normal dietary constituent derived from the side chain of 
chlorophyll) markedly decreases body weight gain and increases weight loss more so in female 
than male WT mice (70-72). This difference has been attributed to the lower expression of the 
protein products of the Fabp1 and/or Scp2/Scpx genes, both of which are involved in phytol 
metabolism (18, 70, 72, 3, 113). With regards to human disease, increased FABP1 level and 
human genetic variation in the Fabp1 gene have been associated with development of NAFLD as 
indicated above. While Scp2/Scpx gene ablation in mice is associated with altered phytol, lipid 
metabolism, and neurotoxicity (3, 18, 70, 73) human genetic variation in Scp2/Scpx also results 
in neurotoxity exhibited as neurodegeneration, brain iron accumulation,  leukencephalopathy, 
dystonia, and motor neuropathy (74, 75). 
Overall in the setting of health as compared to excessive adiposity, our study supports 
that endogenous (sex) and phenotypic (WT vs TKO) factors impact the metabolic functions of 
the genes, Fabp1 and Scp2/Scpx wherein lipid accumulation in mice fed a high fat diet highlights 
 73 
 
the role of Fabp1 and/or Scp2/Scpx genes as potential targets for therapeutic intervention in the 
treatment of NAFLD. 
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APPENDIX I 
CHAPTER III FIGURES 
Chapter III Figure 1. Body Weight, Liver Weight and Serum AST and ALT (Milligan, 2017). 
Percent change in body weight (A), body weight change per energy intake (B), ratio of body weight 
per gram of liver weight (C), liver weight (D) and serum levels of ALT (E) and AST (F) were 
determined for wild-type (WT) and L-FABP/SCP2/SCPx gene ablated (TKO) female mice fed a 
0.5% phytol diet as described in Experimental Procedures. Means +/- SE; n= 8 animals/group; #p 
< 0.05 between phytol-fed WT versus phytol-fed TKO mice. 
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Chapter III Figure 2. Body Composition of Fat Tissue Mass and Lean Tissue Mass (Milligan, 
2017). Whole body phenotype of WT and TKO mice fed a 0.5% phytol diet was determined by 
Lunar PIXImus dual-energy x-ray absorptiometry (DEXA). DEXA resolved whole body fat tissue 
mass (FTM) and lean tissue mass (LTM). A and B are representative images of control diet fed 
WT and TKO mice at the end of the study, respectively. C and D are representative images of 
phytol diet fed WT and TKO mice at the end of the study, respectively. The change in FTM (E) 
and LTM (F) was determined for 8 mice per group. Means +/- SE; n= 8 animals per group; #p < 
0.05 between phytol-fed WT versus phytol-fed TKO mice. 
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Chapter III Figure 3. Hepatic Lipid Levels and Expression of Key Proteins in Glyceride 
Synthesis (Milligan, 2017). WT and TKO mice were fed a 0.5% phytol diet as described in 
Experimental Procedures. Levels of total hepatic lipid (A), hepatic neutral lipid (B), hepatic 
phospholipid (C) and hepatic triacylglycerol (D) were measured and qRT-PCR was performed to 
measure the expression of Gpam (E), Agpat2 (F), Lipin2 (G) and Dgat2 (H) as described in 
Methods. Means +/- SE; n= 8 animals per group; #p < 0.05 between phytol-fed WT versus phytol-
fed TKO mice. 
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Chapter III Figure 4. Hepatic Expression of SREBPs and Target Genes in de novo Fatty Acid 
and Cholesterol Synthesis (Milligan, 2017). Livers from WT and TKO mice fed a 0.5% diet 
phytol diet were examined by western blotting as described in Methods to measure relative hepatic 
protein levels of SREBP1 (A) and SREBP2 (B). The housekeeping gene GADPH or COX4 was 
used as a loading control to normalize protein expression for SREBP1 and SREBP2, respectively. 
Inset in Panels A-B show representative western blots of relative protein expression in each mouse 
group. qRT-PCR was performed to determine relative transcription of SREBP1 target genes Acc1 
(C) and Fasn (D) as well as transcription of SREBP2 target genes Hmgcs1 (E) and Hmgcr (F) also 
as described in Methods. 18S rRNA was used to normalize mRNA expression levels. Means +/- 
SE; n= 8 animals per group; #p < 0.05 between phytol-fed WT versus phytol-fed TKO mice. 
 92 
 
 
 
 
 93 
 
Chapter III Figure 5. Fatty Acid Uptake and Expression of Membrane Fatty Acid Transport 
Proteins (Milligan, 2017). WT and TKO mice were fed a 0.5% phytol diet as described in 
Experimental Procedures. Serum NEFA was measured (A) and western blotting was performed to 
measure the expression of FATP5 (B), FATP2 (C), FATP4 (D), and GOT (E) as described in 
Methods. The housekeeping gene COX4 was used as a loading control to normalize FATP5, 
FATP2 and GOT expression. GADPH was used as a loading control to normalize FATP4 
expression. Insets in Panels B-E show representative western blots of relative protein expression 
in each mouse group.  Means +/- SE; n= 8 animals per group; #p < 0.05 between phytol-fed WT 
versus phytol-fed TKO mice. 
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Chapter III Figure 6. Fatty Acid Oxidation (Milligan, 2017). WT and TKO mice were fed a 
0.5% phytol diet as described in Experimental Procedures. Serum (A) and liver (B) concentrations 
of β-hydroxybutyrate (β-OHB) were determined and western blotting was performed to measure 
the hepatic expression of CPT1A (C), CPT2 (D), catalase (E), p-thiolase (F), SCPx (G and H), 
PPARα (I) and RxRα (J) as described in Experimental Procedures. The housekeeping gene COX4 
was used as a loading control to normalize CPT1A, CPT2 and p-thiolase expression. GADPH was 
used as a loading control to normalize catalase, SCPx, PPARα and RxRα expression. Inset in 
Panels C-J show representative western blots of relative protein expression in each mouse group.  
Means +/- SE; n= 8 animals per group; #p < 0.05 between phytol-fed WT versus phytol-fed TKO 
mice. 
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Chapter III Figure 7. Expression of Proteins in the Cholesteryl Ester Synthesis/Hydrolysis 
Cycle (Milligan, 2017). WT and TKO mice were fed a 0.5% phytol diet as described in 
Experimental Procedures. Levels of total hepatic cholesterol (A), hepatic free cholesterol (B), and 
hepatic cholesteryl ester (C) and were assayed; western blots were performed to measure the 
expression of ACAT2 as described in Experimental Procedures. The housekeeping gene COX4 
was used as a loading control to normalize protein expression. Inset in Panel D shows 
representative western blotting of relative protein expression in each mouse group. qRT-PCR was 
performed to determine relative transcription of the Lipe gene (E) as described in Methods. 18S 
rRNA was used to normalize mRNA expression levels. Means +/- SE; n= 8 animals per group; #p 
< 0.05 between phytol-fed WT versus phytol-fed TKO mice. 
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Chapter III Figure 8.  Serum Lipid and Lipoprotein Levels (Milligan, 2017). WT and TKO 
mice were fed a 0.5% phytol diet as described in Experimental Procedures. Serum levels of free 
cholesterol (A), cholesteryl ester (B), HDL cholesterol (C), apoA1 (D), non-HDL-C (F) and apoB 
(G) were measured and the apoA1/HDL-C (E) and apoB/non-HDL-C (H) ratios were calculated 
as described in Experimental Procedures. Means +/- SE; n= 8 animals per group; #p < 0.05 between 
phytol-fed WT versus phytol-fed TKO mice. 
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Chapter III Figure 9. Expression of Hepatic Proteins Involved in Cholesterol Uptake, Efflux 
and Biliary Secretion (Milligan, 2017). WT and TKO mice were fed a 0.5% phytol diet as 
described in Experimental Procedures. Levels of hepatic apoA1 (A), apoB (B), SR-B1 (C) and 
LDL-R (D were determined by western blotting as described in Methods. The housekeeping gene 
COX4 was used as a loading control to normalize protein expression. Inset in Panels A-D show 
representative western blots of relative protein expression in each mouse group.  qRT-PCR was 
performed to determine relative transcription of Abcg5 (E) and Abcg8 (F) as described in Methods. 
18S rRNA was used to normalize mRNA expression levels. Means +/- SE; n= 8 animals per group; 
#p < 0.05 between phytol-fed WT versus phytol-fed TKO. 
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Chapter III Figure 10. Hepatic Expression of Proteins for Bile Acid Transport (Milligan, 
2017). WT and TKO mice were fed a 0.5% phytol diet as described inMethods. qRT-PCR was 
performed to measure the expression of Oatp1 (A), Oatp2 (B) and Ntcp (C). 18S rRNA was used 
to normalize mRNA expression levels. Western blotting was performed to measure the expression 
of 3αHSD (D), GST (E), LxR (F), MDR (G), BSEP (H), and FxR (I). The housekeeping gene 
COX4 was used as a loading control to normalize protein expression. Inset in Panels D-I show 
representative western blots of relative protein expression in each mouse group.  Means +/- SE; 
n= 8 animals per group; #p < 0.05 between phytol-fed WT versus phytol-fed TKO mice. 
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Chapter III Figure 11. Lipid Binding and Transport Proteins (Milligan, 2017). WT and TKO 
mice were fed a 0.5% phytol diet as described in Methods. Quantitative western blotting was 
performed to measure the expression of L-FABP (A), SCP2 (B) and ACBP (C) as described in 
Methods. Additional western blotting was performed to measure the relative expression of I-FABP 
(D), B-FABP (E), A-FABP (F) and CRABP-1 (G). The housekeeping gene GADPH was used as 
a loading control to normalize protein expression. Inset in Panels D-G show representative western 
blots of relative protein expression in each mouse group. Means +/- SE; n= 8 animals per group; 
#p < 0.05 between phytol-fed WT versus phytol-fed TKO mice. 
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APPENDIX II 
CHAPTER IV TABLES AND FIGURES 
Chapter IV Table 1. Effect of Fabp1/Scp2/Scpx gene ablation and sex on food consumption 
and body weight in mice fed a high fat diet (Milligan, 2018). Male and female WT and TKO 
mice on a C57BL/6NCr background were pair-fed a HFD. Total food consumed, average daily 
food consumption, total body weight (BW) gain, and total body weight (BW) gain/total food 
consumed were obtained as described in Methods. Whole body fat tissue mass (FTM) and lean 
tissue mass (LTM) were determined by Lunar PIXImus dual-energy x-ray absorptiometry 
(DEXA) as described in Methods. WT: wild type; TKO: triple knock out; CO: control diet, HF: 
high fat diet. Values represent the mean ± SEM, n=6-8. *p <0.05 for TKO vs. WT within the 
same diet and sex; ^p<0.5 for control diet vs high fat diet within the same genotype and sex; #p 
<0.05 for male vs. female within the same genotype and diet.  
 Male WT Male TKO Female WT Female TKO 
 CO HF CO HF CO HF CO HF 
Total Food 
Consumed 
(kcal) 
1039 ± 
27 
1143 ± 
19^ 
1021 ± 
28 
1174 ± 
11^ 
943 ± 
15# 
1056 ± 
17^# 
999 ± 
26 
1085 ± 
12^# 
Average 
Daily 
Food 
Consumption 
(kcal/day) 
11.8 ± 
0.31 
13.0 ± 
0.22^ 
11.6 ± 
0.32 
13.3 ± 
0.12^ 
10.7 ± 
0.17# 
11.4 ± 
0.29^# 
12.0 ± 
0.19* 
12.3 ± 
0.13# 
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Total Food 
Consumed 
(%BW) 
11.3 ± 
0.188 
9.3 ± 
0.204^ 
11.6 ± 
0.156 
9.4 ± 
0.147^ 
14.0 ± 
0.197* 
12.3 ± 
0.353*^ 
14.1 ± 
0.331* 
11.8 ± 
0.382*^ 
Total BW 
Gain (g) 
11.0 ± 
0.854 
15.6 ± 
1.351^ 
8.1 ± 
1.407 
14.6 ± 
1.001^ 
4.8 ± 
0.428# 
6.5 ± 
0.586# 
7.4 ± 
0.749 
8.3 ± 
0.527# 
Total BW 
Gain /Total 
Food 
Consumed 
(g/kcal) 
0.0106 
± 
0.0006 
0.0137 
± 
0.001^ 
0.0078 
± 
0.0012* 
0.0125 
± 
0.0009^ 
0.0052 
± 
0.0005# 
0.0063 
± 
0.0006# 
0.0074 
± 
0.0007 
0.0077 
± 
0.0005# 
Total LTM 
Change (g) 
3.5 ± 
0.6 
3.9 ± 
0.4 
2.4 ± 
0.9 
2.9 ± 
0.8 
3.0 ± 
0.3 
3.3 ± 
0.3  
3.0 ± 
0.4 
3.9 ± 
0.4 
Total FTM 
Change (g) 
6.3 ± 
0.5 
11 ± 
1^ 
4 ± 1* 
10.3 ± 
0.6^ 
0.6 ± 
0.2# 
3.3 ± 
0.7^# 
1.3 ± 
0.4# 
2.1 ± 
0.7# 
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Chapter IV Table 2. Effect of Fabp1/Scp2/Scpx gene ablation and sex on liver weight in 
mice fed a high fat diet (Milligan, 2018). Male and female WT and TKO mice on a 
C57BL/6NCr background were pair-fed a HFD. Final liver weight, liver weight/body weight 
(BW) and total liver protein were obtained as described in Methods. WT: wild type; TKO: triple 
knock out; CO: control diet, HF: high fat diet. Values represent the mean ± SEM, n=6-8. *p 
<0.05 for TKO vs. WT within the same diet; ^p<0.5 for control diet vs high fat diet within the 
same genotype; #p <0.05 for male vs. female within the same genotype. 
 Male WT Male TKO Female WT Female TKO 
 CO HF CO HF CO HF CO HF 
Final Liver 
Weight (g) 
1.30 ± 
0.09 
1.16 ± 
0.08 
1.19 ± 
0.1 
1.24 ± 
0.07 
0.9 ± 
0.02# 
0.76 ± 
0.02# 
1.01 ± 
0.06 
0.81 ± 
0.02# 
Final Liver 
Weight/BW 
(g/g) 
0.041 
± 
0.001 
0.031 ± 
0.001^ 
0.041 
± 
0.002 
0.034 ± 
0.001^ 
0.042 ± 
0.001^ 
0.033 
± 
0.001 
0.044 
± 
0.001 
0.034 ± 
0.002^ 
Final Total 
Liver 
Protein 
(mg/g) 
192 ± 
14 
165 ± 
15 
147 ± 
12 
207 ± 
15*^ 
154 ± 7 
151 ± 
7 
143 ± 
8 
154 ± 
14# 
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Chapter IV Table 3. Effect of Fabp1/Scp2/Scpx gene ablation and sex on AST and ALT in 
mice fed a high fat diet (Milligan, 2018). Male and female WT and TKO mice on a 
C57BL/6NCr background were pair-fed a HFD. Final serum AST and ALT were obtained as 
described in Methods. WT: wild type; TKO: triple knock out. Values represent the mean ± SEM, 
n=7. *p <0.05 for TKO vs. WT; #p <0.05 for Male vs. Female. 
 
Male WT Male TKO Female WT Female TKO 
AST 
IU/L 
31 ± 4 118 ± 9* 42 ± 6 79 ± 5#* 
ALT 
IU/L 
35 ± 4 104 ± 7* 27 ± 3 100 ± 10* 
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Chapter IV Figure 1. Effect of Fabp1/Scp2/Scpx gene ablation and sex on gross liver 
pathology in high fat fed mice (Milligan, 2018). Male and female WT and TKO mice on a 
C57BL/6NCr background were pair-fed a HFD. Livers were collected and processed as 
described in Methods. 
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Chapter IV Figure 2. Effects of Fabp1/Scp2/Scpx gene ablation and sex on histological liver 
pathology in high fat fed mice (Milligan, 2018). Male and female WT and TKO mice on a 
C57BL/6NCr background were pair-fed a HFD. Livers were collected and processed as 
described in Methods. 
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Chapter IV Figure 3. Effects of Fabp1/Scp2/Scpx gene ablation and sex on hepatic 
accumulation of lipids in high fat fed mice (Milligan, 2018). Male and female WT and TKO 
mice on a C57BL/6NCr background were pair-fed a HFD.  Levels of total hepatic lipid (A), 
hepatic neutral lipid (B), hepatic phospholipid (C) and hepatic triacylglycerol (D) were measured 
and qRT-PCR was performed to measure the expression of GPAT (Gpam gene) (E), AGPAT 
(Agpat2 gene) (F), DGAT (Dgat2 gene) (H) and Lipin 2 (Lpin2 gene) (H) as described in 
Methods. Values represent the mean ± SEM, n=8. *p <0.05 for TKO vs. WT. #p <0.05 for Male 
vs. Female. 
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Chapter IV Figure 4. Effects of Fabp1/Scp2/Scpx gene ablation and sex on hepatic 
expression of key proteins in lipid synthesis in high fat fed mice (Milligan, 2018). Livers 
from male and female WT and TKO mice on a C57BL/6NCr background pair-fed a HFD were 
examined by western blot to measure relative hepatic protein levels of SREBP1 (A) as described 
in Methods.  The housekeeping gene COX4 was used as a loading control to normalize protein 
expression of SREBP1. The inset in panel A shows representative western blots of relative 
protein expression in each mouse group. qRT-PCR was performed to determine relative 
transcription of the SREBP1 target genes ACC1 (Acaca gene) (B) and FASN (Fasn gene) (C) as 
described in Methods. Values represent the mean ± SEM, n=8. *p <0.05 for TKO vs. WT. #p 
<0.05 for Male vs. Female. 
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Chapter IV Figure 5. Effects of Fabp1/Scp2/Scpx gene ablation and sex on hepatic fatty 
acid oxidation high fat fed mice (Milligan, 2018). Male and female WT and TKO mice on a 
C57BL/6NCr background were pair-fed a HFD. NEFA (A), βHOB (B) and glucose (C) were 
measured as described in Methods. qRT-PCR was performed to determine the relative 
transcription of the lipid oxidative enzymes Cpt1a (D), Cpt2 (E) and Acox1 (F) as described in 
Methods. The nuclear receptors PPARα (G) and RXR (H) were examined by western blot to 
measure relative hepatic protein levels as described in Methods.  The housekeeping gene COX4 
was used as a loading control to normalize protein expression of PPARα and RXR. The inset in 
panels G-H show representative western blots of relative protein expression in each mouse 
group. Values represent the mean ± SEM, n=8. *p <0.05 for TKO vs. WT. #p <0.05 for Male vs. 
Female. 
 
 117 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 118 
 
Chapter IV Figure 6. Effects of Fabp1/Scp2/Scpx gene ablation and sex on hepatic 
cholesterol accumulation in high fat fed mice (Milligan, 2018). Male and female WT and 
TKO mice on a C57BL/6NCr background were pair-fed a HFD. Total C (A), free C (B) and 
cholesteryl ester (C) were measured as described in Methods. qRT-PCR was performed to 
determine the relative transcription of SREBP2 (Srebf2 gene) (D) and ACAT2 (Soat2 gene) (G) 
as described in Methods. Western blots were performed to measure relative hepatic protein levels 
of HMGCS1 (E), HMGCR (F) and HSL (H) as described in Methods.  The housekeeping gene 
COX4 was used as a loading control to normalize protein expression of HMGCS1 and HSL and 
GAPDH was used to normalize HMGCR. The inset in panels E, F and H show representative 
western blots of relative protein expression in each mouse group. Values represent the mean ± 
SEM, n=8. *p <0.05 for TKO vs. WT. #p <0.05 for Male vs. Female. 
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Chapter IV Figure 7. Effects of Fabp1/Scp2/Scpx gene ablation and sex on hepatic 
expression of key proteins in hepatic uptake and efflux/secretion of cholesterol in high fat 
fed mice (Milligan, 2018). Livers from male and female WT and TKO mice on a C57BL/6NCr 
background pair-fed a HFD were examined by western blot to measure relative hepatic protein 
levels of SR-B1 (A), APOA1 (B), ABCA1 (C), ABCG1 (D), ABCG5 (I), ABCG4 (E), LDL-R 
(F), APOB (G), MTP (H) and ABCG8 (J) as described in Methods.  The housekeeping gene 
GAPDH was used as a loading control to normalize protein expression of SR-B1, COX4 was 
used to normalize APOA1, ABCA1, ABCG1, ABCG5, ABCG4, LDL-R, APOB and ABCG8 
and BA was used to normalize MTP. The insets in panels A-J show representative western blots 
of relative protein expression in each mouse group. Values represent the mean ± SEM, n=8. *p 
<0.05 for TKO vs. WT. #p <0.05 for Male vs. Female.  
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Chapter IV Figure 8. Effects of Fabp1/Scp2/Scpx gene ablation and sex on hepatic 
expression of intracellular proteins involved in cytosolic transport of cholesterol in high fat 
fed mice (Milligan, 2018). Livers from male and female WT and TKO mice on a C57BL/6NCr 
background pair-fed a HFD were examined by western blot to measure relative hepatic protein 
levels of FABP1 (A), SCP2 (B), GST (C) and 3αHSD (D) as described in Methods.  The 
housekeeping gene GAPDH was used as a loading control to normalize protein expression of 
FABP1 and GST, BA was used to normalize SCP2 and COX4 was used to normalize 3αHSD. 
The insets in panels A-D show representative western blots of relative protein expression in each 
mouse group. Values represent the mean ± SEM, n=8. *p <0.05 for TKO vs. WT. #p <0.05 for 
Male vs. Female. 
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Chapter IV Figure 9. Effects of Fabp1/Scp2/Scpx gene ablation and sex on serum 
lipoproteins and apolipoproteins in high fat fed mice (Milligan, 2018). Male and female WT 
and TKO mice on a C57BL/6NCr background were pair-fed a HFD.  Levels of serum HDL-C 
(A), apoA1 (B) and non-HDL-C (D) were measured and ratios of apoA1/HDL-C (C) and 
apoB/non-HDL-C (F) were calculated as described in Methods. Values represent the mean ± 
SEM, n=8. *p <0.05 for TKO vs. WT. #p <0.05 for Male vs. Female. 
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Chapter IV Figure 10. Effects of Fabp1/Scp2/Scpx gene ablation and sex on biliary bile 
formation in high fat fed mice (Milligan, 2018). Male and female WT and TKO mice on a 
C57BL/6NCr background were pair-fed a HFD. Hepatic Bile acid (A) was measured as 
described in Methods. qRT-PCR was performed to determine the relative transcription of 
CYPA1 (Cyp7a1 gene) (B) and OATP1 (Slco1a1 gene) (C), OATP2 (Slc227a7 gene) (D) and 
BSEP (Abca11 gene) (F) as described in Methods. Western blots were performed to measure 
relative hepatic protein levels of MRP2 (E) MDR2 (G) and PCTP (H) as described in Methods.  
The housekeeping gene COX4 was used as a loading control to normalize protein expression of 
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MRP2 and PCTP and GAPDH was used to normalize MDR2. The insets in panels E, G and H 
show representative western blots of relative protein expression in each mouse group. Values 
represent the mean ± SEM, n=8. *p <0.05 for TKO vs. WT. #p <0.05 for Male vs. Female. 
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Chapter IV Figure 11. Effects of Fabp1/Scp2/Scpx gene ablation and sex on hepatic 
expression of nuclear receptors nuclear receptors regulating transcription of proteins in 
bile acid synthesis in high fat fed mice (Milligan, 2018). Livers from male and female WT and 
TKO mice on a C57BL/6NCr background pair-fed a HFD were examined by western blot to 
measure relative hepatic protein levels of LXR (A), FXR (B) and SHP (C) as described in 
Methods.  The housekeeping gene COX4 was used as a loading control to normalize protein 
expression of these proteins. The insets in panels A-D show representative western blots of 
relative protein expression in each mouse group. Values represent the mean ± SEM, n=8. *p 
<0.05 for TKO vs. WT. #p <0.05 for Male vs. Female. 
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